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Abstract Amyotrophic lateral sclerosis (ALS), also known as Motor Neuron Disease (MND), is 46 
characterized by the degeneration of both upper and lower motor neurons, leading to muscle weakness 47 
and eventual paralysis. Until recently, ALS was classified primarily within the neuromuscular domain, 48 
although new imaging and neuropathological data have indicated the involvement of the non-motor 49 
neuraxis in disease pathology. In most patients, the mechanisms underlying development of ALS are 50 
poorly understood, although a subset of patients have familial disease and carry mutations in genes that 51 
have various roles in neuronal function. Two disease modifying therapies which can slow disease 52 
progression, are available for the treatment of ALS, but patient management is largely mediated by the 53 
use of symptomatic therapies, such as the use of muscle relaxants for spasticity and speech therapy for 54 
dysarthria. 55 
 56 
 57 
[H1] Introduction 58 
 Amyotrophic lateral sclerosis (ALS) is a heterogeneous neurodegenerative syndrome that is 59 
characterized by the degeneration of both upper (that is, neurons that project from the cortex to the  60 
brain stem and the spinal cord) and lower (that is, neurons that project from the brainstem or spinal 61 
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cord to the muscle) motor neurons leading to motor and extra-motor symptoms (Figure 1). The initial 62 
presentation of ALS can vary between patients; some present with spinal-onset disease (that is, the 63 
onset of muscle weakness of the limbs), but others can present with bulbar-onset disease (characterized 64 
by dysarthria  ? difficulty with speech  ? and dysphagia  ? difficulty swallowing. In most patients, the cause 65 
of ALS is unknown, although some individuals develop familial forms of the disease, which are 66 
associated with mutations in genes that have a wide range of functions, including functions in non-67 
motor cells. In the familial forms of the disease, some of the implicated genes are incompletely 68 
penetrant, and with rare exceptions, genotype does not necessarily predict phenotype 1. Although the 69 
primary symptoms of ALS are associated with motor dysfunction (such as muscle weakness, spasticity 70 
and dysphagia), up to 50% of patients develop cognitive and/or behavioral impairment during the 71 
course of disease and 13% of patients present with concomitant behavioral variant frontotemporal 72 
dementia (bv-FTD)2-4. The high prevalence of cognitive and/or behavioural symptoms, coupled with the 73 
finding of a hexanucleotide repeat expansion in C9orf72 as the major genetic cause of ALS and FTD 5, 6, 74 
have contributed to the re-characterization of ALS as a neurodegenerative, rather than a neuromuscular 75 
disorder, and have signposted the direction of research over the coming decade.  76 
 77 
 The classification of ALS can vary depending on the criteria used. The traditional definitions of ALS 78 
subgroups are based on the extent of upper and lower motor neuron involvement, although other 79 
classification systems include different parameters, such as the site of onset (that is, bulbar or spinal 80 
onset of disease), the level of certainty of diagnosis according to the revised El Escorial Criteria and 81 
heritability (sporadic or familial disease)7. To date, none of these classification systems have 82 
incorporated the cognitive or behavioural symptoms and within each classification system a range of 83 
sub-phenotypes and clinical trajectories can be demonstrated.  84 
 85 
This Primer will review the aspects of ALS that contribute to disease heterogeneity, and will look to the 86 
future of new therapeutic trials that incorporate recent advances in our understanding of this disease 87 
spectrum. For new therapies, the challenge is to define mechanisms of disease amenable to drug 88 
targeting, and to define sub-cohorts of patients that are likely to respond to these new therapeutic 89 
agents. 90 
 91 
 92 
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[H1] Epidemiology 93 
 94 
[H2] Descriptive epidemiology  95 
The majority of population based epidemiological studies for ALS have come from high quality European  96 
patient Registers 8. These European population based Registers have been combined to form the 97 
European ALS Epidemiology Consortium (EURALS), which has provided data comparing the incidence of 98 
ALS between European countries 9. In Europe, the incidence ranges from 2-3 cases per 100,000 99 
individuals. Defined geographical areas are ideally suited to estimate the incidence and prevalence, and 100 
to support more-detailed studies of risk, clinical trajectory, outcome and utilization of services for ALS8. 101 
As ALS is a rare disease, a population-based approach with multiple sources of ascertainment is the best 102 
way to describe the entire phenotypic spectrum 10 as population-based registers provide more complete 103 
information about the disease than datasets from specialist clinics, which are often biased in favour of 104 
younger patients and those with less severe disease  10. Similarly, clinical trial cohorts such as those 105 
collected within the US-based pooled resource open-access ALS clinical trials database  ProACT) dataset 106 
also select for patients with ALS who have better prognosis; survival within these cohorts is ~12 months 107 
longer than that of true population-based cohorts.  108 
 Contrary to earlier assumptions, the incidence of ALS has been shown to differ based on ancestral 109 
origin; studies in populations of European origin have shown a crude incidence of >3 cases per 100,000 110 
individuals 11, 12, but  incidence rates are lower in East Asia (around 0.8 per 100,00) and South Asia (0.7 111 
per 100,000).   In some regions (such as Guam and the Kii peninsula of Japan) the reported incidence 112 
was very high, but dropped substantially over the past 30 years for reasons that remain unclear. In areas 113 
where different ancestral populations live in close proximity (as in Northern America), the incidence 114 
rates of ALS in indigenous populations is particularly low (0.63 cases per 100,000 individuals)13, whereas 115 
reported incidences in regions of relatively homogeneous populations (such as Ireland, Scotland and the 116 
Faroe Islands)  are high (2.6 cases per 100, 000 individuals) 9, 14. 117 
 118 
In addition, variations in the phenotype and natural history of ALS have been reported in different 119 
ancestral populations; indeed reported survival of patients with ALS is much shorter in Europe (24 120 
months) than in Central Asia (48 months) 15.  In addition, admixed populations (that is, populations of 121 
mixed ancestry ) might have lower mortality rates of ALS.  In a population-based study in Cuba, ALS 122 
mortality rate was 0.55 per 100,000 individuals in a mixed population,  but was about 0.9 per 100,000 123 
individuals in white or black individuals 16, confirming the importance of ancestral origin in disease risk.   124 
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In Europe, most men have spinal onset disease, and women have increased propensity for bulbar onset 125 
disease 9. The percentage of individuals with bulbar onset disease is much lower in Asia compared with 126 
Europe, but a North to South gradient has been described in Europe, with higher percentage of 127 
individuals with spinal onset disease in Southern Europe 9. Based on available data, the age of diagnosis 128 
and first symptoms is higher in Europe compared to Asia and South America.  In Europe, the age of 129 
onset peaks at  65 9.   The main limitation of global ALS epidemiology is that almost 80% of studies have 130 
been conducted in Europe and the US, and mainly comprise patient cohorts of Northern European 131 
ancestry. International consortia collecting data in areas with mixed populations and in different 132 
continents will be required to fully elucidate the range of clinical presentations, and to understand the 133 
roles of ancestry, genetics and environmental exposures in ALS causation. 134 
 135 
[H2] Causes of ALS 136 
 137 
[H3] Genetics. ALS is considered a complex genetic disorder with a Mendelian pattern of inheritance in a 138 
proportion of cases, but no discernible family history in the rest. Mathematical models developed using 139 
population-based registers have suggested that individuals with ALS are likely to carry a number of  ?at 140 
risk ? variants that interact with environmental factors through a series of at least 6 notional steps 141 
leading to disease manifestation. One of these steps is thought to be the genetic risk (from birth), but 142 
the interplay of environmental factors that lead to the remaining steps have yet to be defined. In 143 
transgenic mice, the genetic background can alter the phenotypic presentation of ALS  17, 18, suggesting 144 
that human disease phenotypes could also have a genetic  basis, and that genomic and epigenomic 145 
 “ĨŝŶŐĞƌƉƌŝŶƚŝŶŐ ? ĐŽƵůĚ ƉĞƌŵŝƚthe clustering of different phenotypic manifestations into discrete 146 
underlying causes that are amenable to therapeutic intervention.  147 
 148 
Large combined genome-wide association studies (GWAS) of apparently sporadic ALS suggest that the 149 
genetic architecture is based primarily on rare variants, in contrast to other diseases, such as 150 
schizophrenia, which are associated with large numbers of common variants. GWAS in ALS are also 151 
complicated as the rare variants that confer risk might be specific to individuals, families and ancestral 152 
populations 19, rendering GWAS less suited for study of ALS genetics than is schizophrenia. Initiatives 153 
such as the Project MinE Consortium (www.projectmine.com), which aims to undertake whole genome 154 
sequencing of >16,000 patients with ALS and 6,000 control individuals, are likely to provide greater 155 
clarity of the genetic architecture of ALS.  156 
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 157 
Of the known genes of major effect for the development of ALS (Table 1 [  OK), our current knowledge 158 
comes primarily from the study of ancestral European (Europe, USA, Canada and Australia) and East 159 
Asian populations; within these populations,  the dichotomization of ALS into  ?familial ? and  ?sporadic ? 160 
subtypes is an over-simplification. Although at least 30 genes are known to confer a major risk for ALS, 161 
evidence suggests a role of oligogenic inheritance (in which a phenotypic trait is determined by more 162 
than one gene) and of genetic pleiotropy (in which a single gene  has multiple phenotypic 163 
manifestations). Within populations of European extraction, up to 20% of people with ALS have a family 164 
history of either ALS or FTD (Familial ALS) , and of these  4 genes account for up to 70% of all cases of 165 
familial ALS , namely C9orf72, TARDBP (also known as TDP43), SOD1 and FUS 20. However, even in the 166 
case of these known Mendelian inherited genes, familial forms of ALS are often characterized by lower 167 
than 50% penetrance [and genetic pleiotropy, with evidence of oligogenic and polygenic inheritance in 168 
individuals with apparently sporadic disease 21, 22.  169 
 170 
[H3] Environmental and lifestyle factors.  Epidemiological case control studies have sought to 171 
determine the environmental causes of ALS. Early epidemiological studies from regions with a high 172 
incidence of ALS and dementia such as Guam and the Kii peninsula of Japan suggested a role for 173 
neurotoxins  contained within cycad seeds, including ɴ-methylamino-L-alanine  . Although the role of  ɴ-174 
methylamino-L-alanine23 has not been substantiated, a possible role for related cyanotoxins has been 175 
proposed, and exposure to water harbouring cyanobacterial blooms has been suggested to contribute 176 
to risk of ALS in susceptible individuals 24.  177 
 178 
ALS has been reported at a higher frequency among groups of athletes compared to the general 179 
population although whether physical activity is a risk factor for ALS, or a marker of underlying athletic 180 
prowess is unclear. Evidence from a UK study suggests that individuals with ALS had higher rates of pre-181 
morbid  physical activity, but two other European studies suggested either no effect, or a protective 182 
effect 22-24. Reasons for this discrepancy might relate to study design and true population-based 183 
differences. However, because ALS is a rare disease, smaller case control studies are often 184 
underpowered and are subject to both bias and error in interpretation. To address these problems in 185 
study design, a very large case control study  has been completed as part of the EuroMOTOR project 186 
(www.euromotorproject.eu), which has collected >1,500 population-based incident cases and 3,000 187 
matched controls across 3 countries. Analysis is ongoing, although preliminary data suggest that 188 
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exposure to smoking might increase the risk of developing ALS, but type 2 diabetes mellitus, high levels 189 
of circulating lipids and exposure to female contraceptive hormones seem to be protective 25, 26  190 
[H1] Mechanisms/pathophysiology 191 
 192 
[H2] Histopathology  193 
Although the fundamental pathophysiological mechanisms underlying ALS are not well understood, the 194 
neuropathological hallmark of disease is the aggregation and accumulation of ubiquitinated 195 
proteinaceous inclusions in motor neurons . Protein inclusions occur in other neurodegenerative 196 
disorders (such as amyloid plaques in Alzheimer Disease and synuclein-containing Lewy Bodies in 197 
Parkinson Disease. The biological processes leading to formation of these inclusions has been the 198 
subject of intensive research, but is poorly understood 4.  199 
In most subtypes of ALS the tar DNA-binding protein 43 (TDP-43) is the major constituent of these 200 
inclusions, although mutations in TARDBP are a rare cause of ALS 27, 28  Indeed, approximately 97% of 201 
patients with ALS have features of a TDP-43 proteinopathy, with depletion of TDP-43 in the nucleus, but 202 
the formation of cytoplasmic aggregates with skein-like or compact morphology in residual motor 203 
neurons (Figure 2A). In specific subtypes of ALS, other types of protein aggregates might be seen, such 204 
as P62-positive, TDP-43 negative protein inclusions that are caused by dipeptide repeat proteins and 205 
might be seen outside the motor system in patients with (Figure 2C) and neurofilamentous hyaline 206 
conglomerate inclusions (Figure 2B) and the accumulation of misfolded superoxide dismutase (SOD1) in 207 
patients with SOD1-ALS Although protein aggregates are the hallmark of ALS, the high molecular weight  208 
YES ] complexes that precede the formation of the aggregates, rather than the aggregates themselves29, 209 
30, might be the toxic species. Shedding of higher molecular protein complexes might mediate cell to cell 210 
propagation of disease, linking the progression of ALS to a prion-like mechanism, as has also been 211 
suggested for tau and synuclein-mediated diseases 31, 32. 212 
 213 
The gross pathological features of ALS comprise skeletal muscle atrophy, atrophy of the motor cortex 214 
and pallor and sclerosis of the corticospinal and corticobulbar tracts ), together with thinning of the 215 
hypoglossal nerves (which are involved in the control of the muscles of the tongue) and the ventral roots 216 
of the spinal cord. Microscopic examination usually reveals a depletion of at least 50% of spinal motor 217 
neurons and diffuse astrocytic gliosis and microglial infiltration in the grey and white matter of the 218 
spinal cord (Figure 2D AND 2F).  Axonal loss, gliosis and myelin pallor are seen in the corticospinal tracts, 219 
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and astrocytic gliosis is usually observed in the motor cortex, together with variable depletion of upper 220 
motor neurons. Skeletal muscle shows features of denervation and reinnervation, with fibre type 221 
grouping and clusters of angular atrophic fibres.  222 
 223 
 224 
[H2] Overview of pathophysiology OK 225 
Progress has been made in the identification of the genetic causes of ALS21, 22 and models in rat, mouse, 226 
zebrafish, flies, worms and yeast have been developed to study the mechanisms by which gene 227 
mutations cause motor neuron degeneration and to model particular biological processes thought to be 228 
important in disease pathobiology. All of these models have limitations and none fully recapitulates 229 
human disease, which is partly because most models are based on gene overexpression (with multiple 230 
copies of the human variant inserted into the transgenic model) and because the human neuro-axis 231 
differs substantially from that of lower animals. Nevertheless, findings from animal models can 232 
contribute to our understanding of the cell biology underlying neurodegeneration and can open new 233 
avenues towards targeted drug development. In reality, the cellular disruption  in ALS is likely the result 234 
of many different interacting mechanisms that culminate in larger network disruption, and the 235 
separation of different mechanisms is somewhat artificial.  This is exemplified by the finding that 236 
multiple factors can contribute to neuronal damage in models of Sod1 OK MODIFIED BY PJS ?] 237 
mutations (Table 1). The relative extent by which each of these factors contributes to the overall 238 
pathobiology of human disease cannot be fully ascertained, it would be erroneous to assume that  all of 239 
these factors are involved in all cases of ALS, as human disease is heterogeneous. Notwithstanding, each 240 
of the thematic areas should be considered in detail, as they represent our current knowledge base of 241 
the pathophysiology of ALS, and are the drivers of current and future therapeutic initiatives (Figure 3).  242 
 243 
[H2] Impaired protein homeostasis  244 
Mutations in some genes  lead to the translation of proteins that are misfolded, have an abnormal 245 
cellular localization or are aberrantly formed, and that can directly or indirectly impair the proteasome 246 
or autophagy machinery of the cell, leading to impaired cellular protein turnover. Indeed, genes 247 
associated with familial ALS encode proteins that can promote dysfunction of the ubiquitin-proteasome 248 
system. For example, mutant SOD1 is associated with reduced expression of ubiquitin-proteasome 249 
system components 33, valosin-containing protein (VCP) and ubiquilin-2 are involved in substrate 250 
delivery to the proteasome, and this function is disrupted in the presence of ALS-associated mutations 251 
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34-36. In addition, dysregulation of chaperone proteins has been identified in ALS associated with SOD1 252 
and TARDBP mutations 37-40 . Mutations in VAPB (encoding vesicle-associated membrane protein 253 
associated protein B) can cause defective activation of the unfolded protein response in disease models  254 
41, 42.  255 
 256 
C9orf72  is a key regulator of autophagy initiation 43 and loss of this function might contribute to the 257 
presence of ubiquitin and p62 positive, TDP-43 negative inclusions in extra-motor areas of the central 258 
nervous system (CNS) in C9orf72-related ALS. Sequestosome-1, optineurin and ubiquilin-2  have a role in 259 
the early steps of autophagy 44-46, and alsin, polyphosphoinositide phosphatase (FIG4), transitional 260 
endoplasmic reticulum ATPase (VCP) and charged multivesicular body protein 2b (CHMP2B) have roles 261 
in the maturation of autophagosomes into autophagolysosomes by regulating the fusion of 262 
autophagosomes with multivesicular bodies, endosomes and lysosomes lysosomes 47-51. Mutations in 263 
SQSRM might disrupt the correct delivery of autophagic substrates to the autophagosome 52 and 264 
mutations in UBQLN2 and OPTN (which both encode autophagy receptors) are also associated with ALS. 265 
The activities of sequestosome-1 and optineurin are regulated by serine/threonine-protein kinase  266 
(TBK1) and 53, 54 haploinsufficiency of TBK1 [YES is a cause of familial ALS, which supports the hypothesis 267 
that reduced substrate delivery to autophagosomes might contribute to motor neuron injury in ALS. 268 
Reduced VCP activity has been shown to decrease the maturation of autophagosomes. Other proteins 269 
implicated in ALS pathophysiology, including alsin and FIG4 , can affect autophagy at the stage of 270 
initiation, although the mechanism for this is unclear47, 55. Both SOD1 and TDP-43 are known substrates 271 
of autophagy, suggesting that defective autophagy could contribute to the toxic accumulation of these 272 
proteins in ALS. The formation of dipeptide repeat proteins through repeat-associated non-ATG (RAN) 273 
translation from the expanded RNA repeat of the C9orf72  gene might also result in dysproteostasis, but 274 
this remains to be conclusively demonstrated and the mechanism elucidated.  275 
 276 
 [OK  277 
 278 
[H2] Aberrant RNA metabolism  279 
Alteration of mRNA processing is a key theme in ALS pathogenesis56. mRNA undergoes a complex system 280 
of processing as it transits from the nucleus to cytoplasm, where it is translated into protein. In neurons, 281 
mRNAs can be transported to allow local translation in the axonal compartment. Although the 282 
functional consequences of RNA dysregulation that lead to age-related and selective degeneration of 283 
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neuronal populations remain poorly understood, analysis of the translatome of actively transcribing 284 
mRNAs will be essential in elucidating the upstream molecular events contributing to neuronal injury.  285 
 286 
The discovery of mutations in TARDBP and FUS as rare causes of  ALS has identified a crucial 287 
pathogenetic role for RNA binding proteins that contain low complexity domains 57. Mutant TDP-43 or 288 
FUS proteins mislocalize from the nuclear to the cytoplasmic compartment and this is hypothesised to  289 
result in the loss of the normal processing of their target RNAs 58, 59. Indeed, up to one third of the 290 
transcriptome is altered in models of TARDBP-related ALS 60, and dysregulation of gene expression has 291 
also been observed in relation to mutations in C9orf72, SOD1, and FUS 61, including transcription, 292 
alternative splicing of mRNA, axonal transport of mRNAs and biogenesis of microRNAs 62, 63.  293 
 294 
The GGGGCC repeat expansion in the noncoding region of C9orf72 forms stable parallel uni- and 295 
multimeric G-quadruplex structures, which avidly interact with RNA processing factors 64, 65. In addition, 296 
the repeat expansion gives rise to abnormal RNA species that can be identified as nuclear RNA foci and 297 
the C9orf72 mutation might induce direct RNA toxicity, by, for example, sequestering RNA binding 298 
proteins 66-68 . Indeed, a large set of proteins that bind to the expanded repeat have been identified  69. 299 
In addition, repeat expansions could lead to the formation of R-loops (that is, DNA-RNA hybrid 300 
structures) that increase susceptibility to DNA damage and genome instability 70, 71. Indeed, R-Loops and 301 
genome instability due to double strand DNA breaks and defective serine-protein kinase ATM-mediated 302 
DNA repair have been identified as important components of neuronal injury due to GGGGCC repeat 303 
expansion in C9orf72 72 .  304 
 305 
Mutations in ANG (encoding angiogenin, which has a role in RNA processing 73, 74) and SETX (encoding 306 
senataxin, which regulates the transcription of ribosomal RNA 75, 76) are associated with ALS, and might 307 
lead to disturbances in RNA metabolism.  In addition, mutations in [ ELP3 (encoding elongator protein 308 
3), TAF15 (encoding TATA-binding protein-associated factor 2N ) and EWSR1 (encoding RNA-binding 309 
protein EWS  ) 77-79 have also been associated with ALS. These genes encode proteins that are involved in 310 
regulation of RNA metabolism; ELP3 contributes to the regulation of transcription elongation, and TAF15 311 
and EWSR1, which are functionally and structurally related to FUS, have a role in the control of 312 
transcription and alternative splicing 80, 81.  313 
 314 
  11 
  Mutations in other genes involved in RNA metabolism: such as TAF15, EWSR1, hnRNPA1, hnRNPA2B1 315 
and MATR3 have been implicated in ALS 82, 83. The mislocalization of the mutant proteins into the 316 
cytoplasm might result in a toxic gain-of-function, and the effect of these proteins on the formation of 317 
stress granules is an area of intense research effort 84-86 . 318 
 319 
[H2] Nucleocytoplasmic and endosomal transport 320 
In addition to altering RNA metabolism , the GGGGCC repeat expansion in C9orf72  is believed to alter 321 
the intracellular localisation of C9orf72 mRNA. Dipeptide repeat proteins are generated from the repeat 322 
expansion in C9orf72 and interfere with proper nucleocytoplasmic transport and trigger neurotoxicity 323 
via several mechanisms 87, 88. For example, arginine-rich dipeptide repeat proteins  isolated from C9orf72 324 
expansions can induce phase separation of proteins that have a role in RNA and stress granule 325 
metabolism, and produce spontaneous stress granule assembly 89. In addition, increased binding of 326 
mRNA export adaptors to expanded C9orf72 pre-mRNAs might target those pre-mRNAs for nuclear 327 
export, which could allow RNA translation to occur with potential toxicity from the expression of 328 
abnormal dipeptide repeat protein species  68, 90. Indeed, sequestration of the nuclear export adaptor 329 
serine/arginine-rich splicing factor 1 (SRSF1) by the repeat expansion region of the RNA, triggers nuclear 330 
RNA export factor 1 (NXF1)-dependent nuclear export of C9orf72 transcripts retaining the 331 
hexanucleotide repeats, allowing RAN translation to dipeptide repeats in the cytoplasm . Depletion of 332 
SRSF1 in cellular and in vivo models reduces the production of dipeptide repeat proteins and 333 
neurotoxicity 91. 334 
  335 
[H2] Endosomal and vesicle transport  336 
 TDP-43 is involved in the regulation of endosomal trafficking and TDP-43 loss-of-function has been 337 
shown to alter dendritic endosomes , which resulted in reduced and detrimental effects on neuronal 338 
health 92. Mutations in ALS2 (encoding alsin) and UNC13A can alter endosomal and vesicle transport . 339 
Indeed, alsin  is a guanine nucleotide exchange factor for the small GTPase Rab5, and is involved in 340 
endosome trafficking and fusion 55, 93. UNC-13 homolog A  encoded by UNC13A, which  is a risk factor for 341 
ALS), is involved in synaptic-vesicle priming and neurotransmitter release 94.  342 
 343 
[H2] Axon structure and function 344 
The finding of DCTN (encoding dynactin) , PFN1 (encoding profilin 1) and TUBA4A (encoding tubulin 345 
alpha-4A chain ) mutations suggests that abnormalities of proteins that are essential for axonal 346 
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transport are associated with ALS 95-97. In addition, mutations in NEFH  (encoding neurofilament) have 347 
also been described in a small number of patients 98, although whether these mutations are 348 
pathogenetic through axonal dysfunction remains to be seen. Rare mutations in PRPH encoding 349 
peripherin, another cytoskeletal protein, have been suggested to have a role in ALS pathogenesis, 350 
possibly through effects on neurofilament housekeeping including protein cargo trafficking  99, 100.  351 
 352 
[H2] DNA repair 353 
Impaired DNA repair was suggested to have a role in ALS pathophysiology following the identification of 354 
FUS mutations, although the exact role of DNA repair failure in ALS remains to be clarified101, 102. 355 
Mutations in NEK1 and C21orf2 , both of which encode proteins involved in DNA repair, have recently 356 
been identified as causes for ALS 103-105 although the biological pathways associated with their  their 357 
causal role awaits confirmation. 358 
 359 
[H2] Excitotoxicity 360 
Motor neurons are very sensitive to toxicity induced by calcium entry following excessive glutamate 361 
stimulation as they have a lower calcium buffering capacity than other neuronal subtypes and ɲ-amino-362 
3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors that are more calcium permeable (as 363 
they contain less of the GluR2 subunit) 106. In addition, excitatory amino acid transporter 2 (EAAT2), an 364 
astroglial [protein that is the main synaptic glutamate re-uptake transporter, is impaired in ALS, which is 365 
likely to result in synaptic glutamate abundance and motor neuron toxicity. The loss of EAAT2 has been  366 
observed in both rodent models and patients with  familial or sporadic ALS.  Excitotoxicity is thought to 367 
be a mechanism common to all forms of ALS, although the evidence for this remains indirect. One 368 
argument is that riluzole, which can attenuate disease progression and is an approved drug for 369 
neuroprotection in ALS, can inhibit glutamate release 107, 108. However, whether this underlies the 370 
therapeutic effect of riluzole remains unclear.  371 
 372 
[H2] Oligodendrocyte degeneration  373 
Oligodendrocyte degeneration has been observed in ALS. In the healthy CNS, oligodendrocytes are 374 
replaced by the proliferation of oligodendrocyte precursor cells, which are abundantly present 109, 110 . At 375 
least in animal models of ALS, and for reasons that are now clear, oligodendrocyte precursor cells fail to 376 
go through the final stages of differentiation. Oligodendrocytes provide vital metabolic support to axons 377 
through the shuttling of lactate through monocarboxylate transporter 2 111, 112, and accordingly, 378 
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dysfunction of oligodendrocytes contributes to the motor axonal failure in ALS. Restoring 379 
oligodendrocytic function by transgenically deleting mutant SOD1 from these cells significantly slows 380 
disease progression and prolongs their life span 113. In patients with ALS, abnormalities in 381 
oligodendrocytes can occur, but whether these changes contribute to the disease remains to be 382 
demonstrated.  383 
 384 
[H2] Neuroinflammation  385 
 Neuroinflammation can be observed in imaging studies in patients with ALS, human postmortem 386 
samples and rodent models of ALS 114, 115Astrocytes and microglial cells release a number of hazardous 387 
and possibly neuroprotective factors. Deleting mutant Sod1 from these cells in a mouse model increases 388 
survival and slows disease progression 116, indicating that inflammation is an important factor for 389 
amplifying neuronal injury and disease progression in ALS. Microglia have dual activation phenotypes, 390 
which can be neuroprotective (the M2  phenotype) or toxic (also known as classically activated, or M1 391 
phenotype); evidence from SOD1- transgenic mice suggests the phenotype of microglia evolves with 392 
disease progression, from a neuroprotective phenotype at disease onset to a neurotoxic phenotype, 393 
with an altered cytokine release profile, at end-stage disease 117 .  In addition, evidence highlights 394 
complex signalling between CNS resident immune cells and peripheral cells, including monocytes and T-395 
lymphocytes. 396 
[H2] Mitochondrial dysfunction  397 
Mitochondrial function is impaired in ALS and changes in mitochondrial morphology have been shown in 398 
some patients, and in the SOD1 mouse model 118, 119. In the SOD1 model, vacuoles containing protein 399 
aggregates containing mutant SOD1 can be observed in the mitochondrial inter-membrane space, 400 
leading to impairment of protein import 120. In addition, oxidative damage to mitochondrial proteins 401 
leads to defects in respiratory chain function in patients with ALS and in SOD1 mouse models 121, and  402 
various  experimental models of ALS have defects in axonal transport of mitochondria, which could 403 
contribute to the axonopathy at the neuromuscular junction 122, 123.  404 
 405 
Many of the functions disrupted in ALS are regulated by signalling between the endoplasmic reticulum 406 
and mitochondria, underpinned by tight junction associations mediated by the endoplasmic reticulum 407 
protein VAPB and the outer mitochondrial protein regulator of microtubule dynamics protein 124. These 408 
associations are perturbed by TARDBP and FUS mutations125, 126. TDP-43 preferentially binds to mRNAs 409 
encoding respiratory chain complex 1 subunits and causes complex 1 disassembly 127 and accumulates in 410 
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the mitochondria of patients with ALS and mutations in TARDBP increase the mitochondrial localization 411 
of TDP-43. Suppression of TDP-43 localization to mitochondria improves mitochondrial dysfunction and 412 
reduces neuronal loss in mTDP-43 cell based models. In C9orf72-related ALS models, the dipeptide 413 
repeat protein poly(GR) appears to compromise mitochondrial function and causes oxidative stress and 414 
DNA damage 128. CHCHD10 mutations, which are associated with familial ALS, can promote the loss of 415 
mitochondrial cristae junctions, impair mitochondrial genome maintenance and interfere with apoptosis 416 
by preventing of cytochrome-C release 129.  417 
 418 
[H2] Final common pathway 419 
The main mechanism involved in the pathogenesis of ALS is probably dependent on the initial cause, 420 
although multiple mechanisms appear to explain the toxicity of one mutation and these mechanisms are 421 
likely highly interlinked. This is clearly the case for SOD1 mutations. In the case of C9orf72 repeat 422 
expansions, multiple factors likely contribute to neuronal injury including toxic gains-of-function related 423 
to RNA foci and the presence of dipeptide repeat proteins, but loss of the normal function of the 424 
C9orf72 protein might also have a role.  425 
 426 
Whatever the mechanisms of ALS, the end result is that the motor neuron cannot maintain its axonal 427 
projections, leading to axonal retraction and denervation of the target cell. For lower motor neurons, 428 
this results in denervation of the muscle, but for upper motor neurons results in the loss of proper 429 
control of lower motor neurons, hypertonicity and  weakness .. In addition, a loss of important neural 430 
networks within motor and extra-motor domains is also apparent 130.  As many of the proteins encoded 431 
by genes that are implicated in ALS are ubiquitously expressed (Table 1), it is unclear why motor neurons 432 
are the most susceptible to the hazardous effects of these mutations. The large size of motor neurons, 433 
and in particular the need to maintain their long axonal projections, could make these cells more 434 
sensitive to metabolic abnormalities than others, but other neuronal subtypes, such as sensory neurons, 435 
have even larger axonal projections.  Other factors that have been suggested to have a role are the high 436 
expression of EphA4 and matrix metalloprotein 9  and the low expression of osteopontin and insulin-like 437 
growth factor 2  by motor neurons, which might limit axonal sprouting and repair. Of particular interest 438 
is that within the motor neuron pool, neurons that establish the fast fatiguable motor units die first in 439 
ALS 131, 132 , but how this relates to the other vulnerability factors needs to be clarified.  440 
 441 
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[H1] Diagnosis, screening and prevention 442 
 443 
[H2] Clinical presentations  444 
 The clinical hallmark of ALS is the involvement of both upper and lower motor neurons (Figure 1). 445 
Patients can present with symptoms of an upper motor neuron predominant onset (that is, spasticity 446 
and weakness) in whom lower motor neuron involvement only becomes evident at later stages of 447 
disease. 7, 133-136  . Conversely, patients can present with symptoms of lower motor neuron dysfunction, 448 
which includes fasciculations, cramps and muscle wasting. Approximately one third of patients with ALS 449 
present with bulbar-onset disease, which is characterized by progressive dysarthria, followed by 450 
difficulty swallowing and often with associated emotional lability. Limb onset disease accounts for 60% 451 
of cases, is usually asymmetrical in presentation and can first develop in the upper or lower limb. [Up to 452 
5% of patients present with respiratory problems and are often seen first in cardiology and pulmonology 453 
clinics prior to their referral to neurology clinics 137. In these cases, patients can also present with 454 
unexplained weight loss. Evidence suggests that some patients with ALS are hypermetabolic; 138 455 
although the pathophysiology underpinning this is not well understood.  Cardiovascular risk factors 456 
(such as hyperlipidemia or obesity) might attenuate risk 138, but do not alter clinical outcome 139 . 457 
Patients can present with a pure motor phenotype of ALS, and have normal cognition and behaviour, 458 
but some patients can present with a purely cognitive or behavioural phenotype consistent with 459 
frontotemporal dementia(FTD) ), or a mixed phenotype with minor changes in executive impairment 460 
that progress over time. Frontotemporal dementia is part of the presenting features of 13% of incident 461 
cases 2-4 and approximately 30% of all incident patients have some evidence of executive dysfunction at 462 
the time of first presentation 3, 140. Depending on the population and the extent of cognitive testing 463 
performed, most studies have suggested that up to 50% of patients can remain cognitively normal 464 
throughout the course of the disease 3 Behavioural changes are common in patients with ALS, with 465 
apathy as the most prevalent symptom. Detailed examination of behavioural changes in patients with 466 
ALS, using a disease specific behavioural scale (that is, the Beaumont Behavioural Index) suggests that 467 
up to 40% of incident cases have new behavioural changes that can be clustered into at least 5 different 468 
groups which roughly map to known neuroanatomical networks and pathways 141. Substantial 469 
autonomic impairment (such as cardiovascular, gastrointestinal and bladder dysfunction) does not occur 470 
in the majority of patients with ALS.  471 
 472 
[H2] Diagnostic criteria  473 
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No definitive test for the diagnosis of ALS is available, and diagnosis is a process of clinical investigation 474 
to exclude other possible causes of the presenting symptoms, combined with evidence of disease 475 
progression. However, the growing understanding of the extra-motor features of ALS, the presence of 476 
phenotypic overlap with other neurodegenerative diseases and the identification of genetic and 477 
pathological subtypes of ALS can confound accurate and timely diagnosis 7.  478 
 479 
Diagnosing ALS is based on the El Escorial criteria (Box 2) 142. Diagnosis according to these criteria 480 
requires a history of progressive weakness spreading within a region or to other regions (such as bulbar 481 
regions (speech and swallowing), cervical regions (upper limbs), thoracic regions (chest wall and 482 
abdominal muscles) or lumbar regions (lower limbs), with evidence of lower motor neuron (through the 483 
presence of specific symptoms or evidence of denervation on electromyography) and upper motor 484 
neuron (through the presence of specific symptoms and brisk deep tendon reflexes) involvement  In the 485 
original criteria, diagnostic certainty ranged from Suspected ALS, (although this is no longer included in 486 
the revised criteria), to Definite ALS (in which three body regions with mixed upper and lower motor 487 
neuron findings were observed), which relates to the burden of disease. Neurophysiological findings 488 
have been classified using the Awaji Criteria, which can enhance diagnostic and prognostic sensitivity 143. 489 
Variants of the El Escorial criteria are used in research settings and for the purposes of clinical trial 490 
enrolment, but these criteria  should not be routinely used in clinical practice for routine patient 491 
ŵĂŶĂŐĞŵĞŶƚ ?ĂƐ  “ƉŽƐƐŝďůĞ>^ ?ĚĞƐĐƌŝďĞĚďǇƚŚĞĐƌŝƚĞƌŝĂ ŝƐĂůŵŽƐƚĂůǁĂǇƐ>^ clinically 144, 145. Genetic 492 
testing can also be included in patients with a strong family history of ALS 146 and clinical evidence of 493 
disease, although this is not uniformly applied across centres 147.  494 
 495 
[H2] Cognitive and behavioural deficits  496 
Standard diagnostic and stratification parameters for ALS do not yet include cognitive or behavioural 497 
status, which is altered in up to 50% of cases (depending on the extent of cognitive and behavioural 498 
assessment  2-4. Various screening tools have been designed to identify patients with ALS and cognitive 499 
and behavioural changes in the clinic, such as the Edinburgh Cognitive and Behavioural ALS Screen 500 
(ECAS), which is validated in several languages and is widely used, as it has a high degree of sensitivity 501 
with lower degrees of specificity 148. Individuals with abnormal ECAS scores (after adjustment to 502 
population-based and educational norms) should be referred for a full neuropsychological evaluation 149. 503 
The detection of cognitive and behavioural changes is important for patients with ALS and their 504 
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caregivers, as executive impairment is associated with a more-rapid disease trajectory and behavioural 505 
changes are associated with higher caregiver burden 150.  506 
 507 
[H2] Biomarkers  508 
As ALS is a clinical syndrome with a heterogeneous phenotypic manifestation [and clinical course, 509 
diagnostic and prognostic biomarkers are urgently required for the purposes of stratification. Levels of 510 
neurofilament light chain (NfL) and phosphorylated neurofilament heavy chain in the cerebrospinal fluid 511 
(CSF) can differentiate patients with  ALS from those with mimics including cervical myelopathy, 512 
multifocal motor neuropathy and inclusion body myositis, with moderate sensitivity and specificity, and 513 
levels have a moderate correlation with disease progression  151-153. However, CSF neurofilament levels 514 
are not integrated into standard clinical practice. Levels of NfL in serum are sensitive and specific for 515 
separating patients with ALS from healthy controls, but data on comparison with ALS mimics are not  516 
available.  517 
 518 
MRI studies of patients with ALS have shown corticospinal tract degeneration, with extensive 519 
involvement within the frontal and temporal regions and basal ganglia, compared with controls  520 
Evidence suggests that selective network vulnerability of structural and functional  ?connectomes ? could 521 
drive the clinical manifestations of ALS, such as vulnerability of the corticospinal, orbitofrontal, 522 
orbitotemporal and frontostriatal circuits 154-156. The presence of network disruption is also supported by 523 
findings using spectral electroencephalogram 130, and that patients with different degrees of cognitive 524 
impairment show significantly different patterns of frontal lobe metabolic impairment on 18F 525 
fluorodeoxyglucose PET imaging 157. However, neither imaging nor spectral electroencephalogram can 526 
provide individualised data that can be used as a reliable biomarker of upper motor neuron dysfunction 527 
and of cognitive impairment in patients with ALS.  528 
 529 
[H2] Differential diagnosis  530 
The differential diagnosis in patients with pure  bulbar pure upper motor neuron or pure lower motor 531 
neuron presentations includes ALS variants, treatable ALS mimics and disorders with a more benign 532 
prognosis 134, 158. Other forms of motor neuron disease include progressive muscular atrophy (that is, the 533 
exclusive degeneration of lower motor neurons) and primary lateral sclerosis (that is, the exclusive 534 
degeneration of upper motor neurons). Some patients with progressive muscular atrophy have 535 
mutations in genes associated with ALS159. Similarly, patients with primary lateral sclerosis may have a 536 
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family member with ALS  and most autopsies of patients with primary lateral sclerosis show subtle signs 537 
of ALS pathology in the lower motor neurons within the brain stem and  spinal cord 135, 158.  538 
 539 
Several conditions have similar initial clinical features as ALS and should be considered in the differential 540 
diagnosis 145, including cervical myelopathy, multifocal motor neuropathy, myasthenia gravis, Lambert 541 
Eaton myasthenic syndrome and inclusion body myositis. Features that should alert the clinician to a 542 
possible mimic syndrome include presentation with of symmetrical findings; prominent extensor plantar 543 
responses (which should raise suspicion of a cervical myelopathy)  and the presence of sensory findings. 544 
Although sensory symptoms are common in ALS, clinical evidence of sensory loss is atypical and should 545 
trigger further investigations. In addition, the presence of substantial weakness in the absence of 546 
wasting  ? which is common in multifocal motor neuropathy and myasthenia gravis  ? and the presence 547 
of disproportionate involvement of quadriceps  ? which is common in inclusion body myositis  ? may 548 
indicate the presence of an ALS mimic syndrome 160. As ALS is a progressive disease, failure of the 549 
condition to progress over months should also trigger a re-investigation 161. 550 
 551 
[H2] Staging and prognosis   552 
Several different staging systems for ALS have been described (Figure 4) 162-165, including the KŝŶŐ ?Ɛ553 
system, which is based on the number of affected regions of the body, and the Milano-Torino system 554 
(MITOS), which is based on a clinical scale The prognosis of ALS is highly variable and prognostic 555 
algorithms have been generated from population-based and clinical trial-based datasets 166, 167. Negative 556 
prognostic indicators include bulbar or respiratory onset disease, the presence of executive impairment 557 
or frontotemporal dementia and weight loss.  Several biochemical markers of prognosis have been 558 
reported including serum urate, serum creatinine, serum chloride, and increased serum and CSF 559 
neurofilament levels 153, 168-170 Declining respiratory function, measured by slow vital capacity, forced 560 
vital capacity and sniff nasal inspiratory pressure also correlate with short survival 166, 167, 171, 172.  561 
[H2] Clinical genetics and predictive testing  562 
Consensus guidelines recommend genetic testing of probands with ALS who have a first or second 563 
degree relative with ALS and/or frontotemporal dementia 19, 173. As the genetic risk for ALS depends on 564 
ancestral origin, the genetic testing should be contextualized; for example, C9orf72 variants are rare in 565 
Asia, whereas mutations in OPTN are more common in Asian than in European populations. Although 566 
the potential benefits of genetic testing for patients are clear and could improve knowledge about their 567 
disease, family planning and their possible inclusion in clinical trials, individuals also have a right not to 568 
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know their genetic status. Pre-symptomatic testing of family members of patients with ALS remains 569 
controversial. Guidelines for genetic testing in research settings have been published 174, but most 570 
centres do not advocate routine testing outside of specialist centres 147. 571 
 [H1] Management 572 
 573 
ALS management is best achieved by a multidisciplinary approach to care, comprising a clinical team 574 
with different specialities, including neurologists, psychologists, nutritionists, pulmonologists, physical 575 
therapists, speech therapists and specialized nurses175, 176. Multidisciplinary care increases survival 177-179, 576 
reduces the number of hospital admissions and shortens hospital stays 178 and increases quality of life of 577 
patients with ALS 180. This is likely related to the optimization of pharmacological and non-578 
pharmacological interventions   and enhanced adherence to treatment guidelines.  579 
 580 
[H2] Disease-modifying therapies  581 
Although > 50 drugs with different mechanisms of action have been studied for the treatment of ALS, 582 
only 2 compounds (riluzole and edaravone have come to market. The negative results of these trials 583 
might include clinical and pathogenetic heterogeneity in disease, and faults in trial design 181.  584 
Riluzole was the first FDA approved treatment for ALS, and, although the mechanism of action is poorly 585 
understood, is speculated to reduce glutamatergic neurotransmission, by blocking voltage-gated sodium 586 
channels on presynaptic neurons. . In the original trial, Riluzole,  increased 18-month survival of patients 587 
by 3 months compared with placebo , but had no significant effect on muscle strength 182. Riluzole is a 588 
relatively safe drug, although the most common adverse effects are an increase in liver enzymes and 589 
asthenia (that is, a lack of energy) and some cases of fatal hepatic failure and pancreatitis have been 590 
reported. In addition to the traditional tablet form of the drug, an oral suspension has been produced 591 
and marketed in some countries for patients who are unable to swallow solid forms of the drug, owing 592 
to severe dysphagia 183. Edaravone, which is thought to act as an anti-oxidant agent  has a beneficial 593 
effect on progression  in a highly selected cohort of patients with early onset and rapidly  progressive 594 
disease  184, and accordingly, has been licensed by the US FDA but not by the European Medicines 595 
Agency.   Whether edaravone should be provided to all patients of ALS regardless of clinical 596 
presentation is a matter of debate 185  597 
 598 
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 [H2] Symptomatic treatments  599 
Other symptoms of ALS can be treated with pharmacological and non-pharmacological interventions. 600 
Nuedexta may improve bulbar function 186 and is available in the US but not in Europe. However, most 601 
of these therapies  for the symptoms of ALS have not been tested in randomized controlled trials and 602 
are based on management  of other diseases.  603 
 604 
 [H3] Spasticity. Spasticity is present in most patients with ALS, but only a small proportion need 605 
treatment. The most commonly used drugs are baclofen and tizanidine (both of which are muscle 606 
relaxants) although no randomized controlled trials in patients with ALS have been conducted. When 607 
patients have severe, disabling spasticity, baclofen can be administered through an intrathecal pump. . 608 
Cannabinoids have been approved  for the treatment of spasticity in patients with multiple sclerosis and 609 
are also used off-label or as a self-prescribed medication in patients with ALS187.  610 
 611 
[H3] Sialorrhoea. Sialorrhoea (that is hypersalivation), causing drooling and the pooling of saliva within 612 
the oral cavity is one of the most disturbing symptoms in patients with ALS, and is more commonly 613 
observed in patients with bulbar-onset disease and during late-stages. Sialorrhoea can be treated [with 614 
anticholinergic drugs, such as scopolamine, atropine, hyoscine, amitriptyline and glycopyrrolate. 615 
Adverse effects associated with the use of anti-cholinergics include blurred vision, mouth dryness and 616 
constipation, and these drugs are contraindicated in patients with heart conduction disturbances and 617 
prostatic hypertrophy. In patients in whom pharmacological treatments are ineffective or are not 618 
indicated, botulinum toxin A or B injections into the salivary glands can used to treat sialorrhoea188, 189. 619 
Salivary gland irradiation has been also proposed 190.  620 
 621 
[H3] Pain. Pain is reported in 15 ?85% of patients with ALS, depending on the duration of the disease  622 
and the setting of the study, and is more frequently of nociceptive than of neuropathic origin. 191 623 
Depending of the type of pain, pharmacological treatments include gabapentin, pregabalin and tricyclic 624 
antidepressants (for neuropathic pain), and NSAIDs, opioids and cannabis for nociceptive pain), but no 625 
randomized controlled trials evaluating treatment of pain in patients with ALS are available. Nociceptive 626 
pain can be also treated with intra-joint injections of lidocaine or steroids, and physical therapy, 627 
including assistive range-of-motion exercises.  628 
 629 
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[H3] Muscle cramps. Muscle cramps are the main cause of pain in about one-quarter of patients with 630 
ALS (mainly patients with the spinal onset disease) and are caused by the instability of motor units 192. 631 
Commonly used treatments for muscle cramps include quinine sulphate, levetiracetam and mexiletine. 632 
Indeed, mexiletine has been shown to induce a significant dose-dependent reduction in muscle cramps  633 
in a phase 2 randomized controlled trial in patients with ALS 193. Of note, the FDA has advised against the 634 
use of quinine sulphate for the treatment of cramps because it can cause cardiac arrhythmias, 635 
bradycardia and prolongation of Q-T interval.  636 
 637 
[H3] Dysphagia 638 
Dysphagia is reported by about 60% of patients with spinal onset ALS, within two years from onset and 639 
100 % of patients with bulbar-onset disease 194. Several strategies can be implemented to reduce the 640 
effects of dysphagia in patients, including dietary changes such as modification of the consistency of the 641 
diet, the use of fluid thickeners and prescription of high-protein and high-caloric supplements, 642 
swallowing facilitating manoeuvers and exercises (such as oral and pharyngeal range-of-motion 643 
exercises, head postures and the technique of supraglottic swallow). An option for severe difficulties 644 
with swallowing is to use enteral nutrition via the insertion of a gastrostomy tube. No established 645 
criteria are available for the initiation of enteral nutrition in patients with ALS, but weight loss of >5% or 646 
unsafe swallowing are generally considered to be red flags that should prompt intervention. 175. Several 647 
techniques are available for minimally invasive tube insertion and open surgery is not recommended 195, 648 
196. Parenteral nutrition provided through a central venous catheter is an alternative to enteral nutrition 649 
in patients with ALS who have severe respiratory insufficiency for whom PEG  are contraindicated 197, 198.  650 
 651 
[H3] Dysarthria. Dysarthria is the presenting symptom in 30% of patients and is found in > 80% of 652 
patients during the course of the disease, up to complete anarthria. Speech therapy can delay the 653 
progression of dysarthria  and  augmentative-alternative communication  [techniques such as 654 
customised  software are the treatment of choice and can enhance quality of life in the most advanced 655 
phases of ALS 199. Communication techniques based on brain-computer interfaces (BEST LEAVE THIS IN 656 
PLACE] have been developed, but their use in the clinical setting is still very limited as their effectiveness 657 
has not been definitely demonstrated 200. Moreover, the use of brain-computer interfaces might be 658 
hindered ďǇƉĂƚŝĞŶƚƐ ?ĐŽŐŶŝƚŝǀĞĚǇƐĨƵŶĐƚŝŽŶŽƌŽůĚĂŐĞ 201. 659 
 660 
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[H3] Deep venous thrombosis. Patients with ALS have leg weakness and reduced mobility, which can 661 
increase the risk of symptomatic and asymptomatic deep venous thrombosis (DVT). The annual 662 
incidence of DVT in patients with ALS ranges from 2.7 to 11.2% 202, 203. In the absence of specific studies 663 
on the prevention and treatment of DVT in ALS general guidelines should be applied, including the use 664 
of compression stockings and anticoagulation therapies  665 
 666 
[H3] Mood alterations. Depression is a relatively common symptom in patients with ALS and has been 667 
found in up to 50% of patients. Depression is generally treated with selective serotonin reuptake 668 
inhibitors (SSRI) or tricyclic antidepressants. Pseudobulbar affect (that is, episodes of uncontrollable 669 
crying or laughing) is a distressing symptom that has been reported in up to 50% of patients with ALS 204 670 
[and can be treated with  SSRIs and tricyclic antidepressants, although this is off-label. 671 
Dextromethorphan (a sigma-1-receptor agonist and an uncompetitive NMDA receptor antagonist) and 672 
low-dose quinidine were effective in reducing symptoms  of pseudobulbar affect by 50% in patients with 673 
ALS or those with multiple sclerosis 205.  674 
 675 
[H3] Cognitive impairment. Cognitive impairment, in particular frontotemporal dementia, is one of the 676 
most disabling symptoms in patients with ALS. No pharmacological therapy is effective for the treatment 677 
of frontotemporal dementia, and acetylcholinesterase inhibitors, which are used for Alzheimer disease, 678 
are not effective. However, some symptoms of frontotemporal dementia can be pharmacologically 679 
treated; evidence suggests SSRIs might help to control the loss of inhibition, overeating and compulsive 680 
behaviour, and antipsychotics can be used to reduce restlessness. Education of caregivers about the 681 
symptoms of frontotemporal dementia can be useful to help the management of patients at home 206. 682 
 683 
[H3] Respiratory insufficiency.  684 
The vast majority of patients with ALS die from respiratory failure. Non-invasive ventilation is the 685 
symptomatic treatment of choice for respiratory failure, and provides significantly longer survival 686 
compared to those who do not use NIV (316 vs 229 days) and improves quality of life 207 208. Accepted 687 
criteria for starting non-invasive ventilation are symptoms or signs related to respiratory muscle 688 
weakness (such as, dyspnoea, orthopnoea or daytime fatigue), a vital capacity of < 80% of predicted 689 
levels, PaCo2 > 45 mmHg, SaO2 <  ? ?A?ĚƵƌŝŶŐA? 5% of sleep time  176. One distressing symptom that is 690 
related to respiratory muscle weakness in patients with ALS is the inability to cough effectively. This can 691 
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be controlled by the use of cough-assist devices, such as the breath-stacking technique or a mechanical 692 
insufflator-exsufflator 209.  693 
 694 
[H2] End of Life Management  695 
The end of life phase for patients with ALS can be difficult to define, although recent staging systems 696 
including KINGS and MITOS  are useful in this regard. The end of life period can be particularly 697 
challenging and is characterized by substantial mobility, communication and, in some cases, cognitive 698 
difficulties. An early discussion of end of life issues will ensure that patients can communicate their 699 
wishes before the onset of substantial communication and cognitive difficulties, can avoid unwanted 700 
interventions or procedures, and can provide time for reflection and the integration of choices within 701 
ƚŚĞƉĂƚŝĞŶƚ ?ƐƉƌŝŽƌŝƚŝĞƐĂŶĚůŝĨĞƉůĂŶƐ ?/ŶĂĚĚŝƚŝŽŶ ?ƐƵĐŚĚŝƐĐƵƐƐŝŽŶƐĐĂŶĂůůĞǀŝĂƚĞƉĂƚŝĞŶƚ ?ƐĨĞĂƌƐ, especially 702 
around fatally choking. The attitudes, culture and personal values of patients, caregivers and health care 703 
providers can influence the timing and content of end of life discussions, decision-making and the 704 
ƉĂƚŝĞŶƚ ?Ɛacceptance or refusal of interventions and treatment options. Some patients with ALS might 705 
choose life-prolonging measures, but others might contemplate life-limiting procedures; the availability 706 
and utilization of different interventions and technologies, such as assisted death and tracheostomy, 707 
varies across centres and between countries. Advance care directives are recognized as important at 708 
end of life in ALS, and provide patients with the option to exercise autonomy regarding preferred end of 709 
life management strategies. Formal care at the end of life should aim to maximize quality of life of both 710 
the patient and caregiver and, where possible, incorporate appropriate multidisciplinary care including 711 
palliative care options.  712 
 713 
[H1] Quality of Life 714 
 715 
Much of the effort of physicians and other health care providers is focused on optimizing the quality of 716 
life (QOL) of patients with ALS. The choice of a specific QOL instrument is complex, and has been 717 
reviewed 210. The perception by individuals with ALS of their QOL takes shape at the time of disclosing 718 
the diagnosis, and can be influenced by the manner in which they are informed . Well-recognized 719 
systematic approaches are available, such as the SPIKES approach, that can convey the diagnosis in a 720 
less distressing manner and can leave the patient feeling hopeful and supported 211-213.  721 
 722 
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 Health-related QOL (HRQOL) ƌĞĨĞƌƐƚŽĂŶŝŶĚŝǀŝĚƵĂů ?ƐƉĞƌĐĞƉƚŝŽŶof their QOL as a function of physical 723 
and mental well-being 214; measures of HRQOL generally decline as ALS advances 210, 215. In contrast, 724 
OQOL encompasses medical factors and a wide variety of non-medical factors, such as family, friends, 725 
occupation, financial well-being, spirituality or religion and existential concerns 216. Patients with ALS 726 
often view their OQOL as good, which persists despite the progression of physical disability 217, 218. This 727 
might be explained by a  ?response shift ? ?also called a frame shift or well-being paradox), whereby the 728 
individual recalibrates the factors that are deemed meaningful to maintenance of their QOL. Most 729 
commonly, this centres around the decreased importance of physical activities and the greater role of 730 
interactive and existential factors, such as social relationships and spirituality 219-221. However, not all 731 
patients maintain a high QOL with advancing illness. Many factors can negatively affect QOL in patients 732 
with ALS, identifying potential areas for intervention, although other factors can improve QOL (Figure 5) 733 
180, 207, 214, 222-228  734 
 735 
Despite good QOL of patients with ALS in aggregate  , psychological health is, on average, poorer than 736 
that of the population as a whole 229. This has substantial implications as depression, hopelessness and 737 
anxiety all associated with a poor QOL.  Psychological interventions have been less well studied230 and  738 
this warrants further attention.  739 
 740 
  741 
QOL can affect the wishes for care of patients with ALS at the end of their lives. In a study from the 742 
Netherlands, 16.8% of patients with ALS chose physician-assisted death, common reasons for which 743 
were hopelessness, loss of dignity, dependency on others and fatigue 215. Similarly, the decision for 744 
euthanasia in patients with ALS in Washington State was driven by loss of autonomy, participation in 745 
enjoyable activities and dignity 216. These studies do not prove poor QOL in these individuals, but they 746 
do raise this as a concern. The quality of death in patients with ALS has been studied less 747 
comprehensively. Death was perceived as peaceful by 88% to 98% of caregivers in Germany, the United 748 
Kingdom, the United States and Canada 217, 231.However, caution must be used in interpreting grouped 749 
statistics. Incompletely relieved symptoms such as coughing from mucus, restlessness, anxiety and 750 
muscle cramps resulted in moderate to severe suffering in the last 24 hours of life in 8 of 171 patients 751 
217.  752 
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 753 
 [H1] Outlook  754 
 755 
The knowledge of ALS and the care of patients with this condition have increased substantially in recent 756 
years, and this trend is likely to continue. 25 years ago, riluzole had not been enrolled in a clinical trial, 757 
non-invasive ventilation was not in routine use for patients, the pathological basis of ALS as a TDP-43 758 
proteinopathy was unknown and no genetic causes for ALS had been identified. In addition, the El 759 
Escorial criteria were not developed, no simple ALS functional scale existed, multidisciplinary care was in 760 
its infancy and the recognition of cognitive change in patients with ALS was limited, and the link with 761 
frontotemporal dementia was not made. What will be different in another 25 years, and how much of 762 
what we regard as self-evident now, will be overturned, is tempting to consider. 763 
 764 
[H2] Epidemiology 765 
We can expect that the numbers of patients with ALS will increase in the future 218, and that population 766 
differences in incidence and phenotype will be recognized. Better multidisciplinary care and an 767 
improved understanding of interventions means that a patient diagnosed with ALS can expect to live 768 
longer than previously. In addition, the development of new drugs to improve respiratory function or 769 
directly affect the disease process are expected to improve survival.  770 
 771 
[H2] Pathophysiology 772 
A big barrier to effective ALS treatments is due to our lack of knowledge of the pathological pathways 773 
that lead to the disease, and how they affect the overall integrity of brain networks. Our understanding 774 
of ALS is improving, including contextualizing the role of TDP-43, the importance of RNA processing for 775 
motor neurons, the spread of disease and the molecular cascades that lead to neuronal death. The 776 
development of new cellular and animal models of ALS is beginning to lead to improvements in our 777 
understanding of the disease , both because the molecular pathways can be dissected more easily, and 778 
because the models can be used to more effectively to identify drugs worth enrolling into human trials. 779 
These insights are the result of genetic findings, which have led to experiments aiming to understand 780 
how loss-of normal protein function and gain-of toxic function cause ALS. As the number of genes 781 
implicated in ALS increases and laboratory models improve, we can expect to design new drugs to 782 
intervene in those pathways.  783 
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 784 
Indeed, our understanding of the genetics of ALS has transformed over the last 25 years, with the 785 
finding that both familial and sporadic ALS have a genetic basis and the number of validated involved 786 
genes steadily increasing. These findings are in large part due to the willingness of the ALS research 787 
community to collaborate, which has generated the huge datasets required for credible gene discovery. 788 
The finding that the genetic architecture of ALS includes an important role for rare genetic variation has 789 
consequences for the likelihood that gene therapy could be effective in this disease. Indeed, as rare 790 
variants are more likely to have a large effect on the risk of disease and can be directly manipulated by 791 
gene therapy, we can expect to see precision medicine spearheaded by targeted gene therapies. 792 
The relationship between ALS and cognitive, cerebellar, autonomic and other non-motor changes is an 793 
area of research that is expected to grow. One consequence of this research is that ALS is probably 794 
primarily a disease of neural networks, which is defined by the involvement of upper and lower motor 795 
neurons, but that can also affect other cell populations and neuronal networks. We can also expect an 796 
increased understanding of the role of inflammation in ALS, both in triggering disease and influencing 797 
the rate of progression.  798 
 799 
[H2] Diagnosis and prognosis 800 
The use of biomarkers for ALS has been investigated for many years, although our understanding has 801 
only recently matured for research to yield useful results.  Diagnostic biomarkers would be useful for 802 
individuals with an atypical or complicated presentation, biomarkers for prognosis would be useful for 803 
planning treatment options, and biomarkers of disease progression would be useful for monitoring 804 
response to existing therapies or potential new therapies in a clinical trial. New signal analysis based 805 
technologies will become available as biomarkers that can image the living human brain 139. 806 
 807 
[H2] Management  808 
 809 
[H3] Clinical Trials  810 
 The validity of pre-clinical studies should be evaluated rigorously by evidence-based analyses, and 811 
translation of new therapies to humans should be undertaken only if findings are robust and 812 
reproducible. Moreover, as ALS is a human disease, testing safe candidate compounds without prior 813 
testing in animal models could be undertaken. In this instance, careful phase I and 2 studies including 814 
detailed pharmacokinetic studies with extensive dose-finding and toxicity studies will be needed. As 815 
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some previous ALS clinical trials failed due to faulty trial design, a detailed correlative analysis of drug 816 
levels in serum and CSF should be undertaken in early phases trials, and all trials should include a 817 
biomarker readout to confirm that the drug is reaching its target.  818 
 819 
 The failure of previous clinical trials for ALS could also result from disease heterogeneity. Methods to 820 
stratify patients that have a shared pathobiology are urgently required, and in the absence of this, pre-821 
specified, post-hoc analyses should be used to identify potential responder groups. This is exemplified 822 
by a recent successful Phase 3 trial of edaravone 184, as recruitment to this trial was based on a post-hoc 823 
analysis to identify possible responders, and stringent recruitment criteria were used to provide a 824 
clinically homogeneous population that were likely to respond to treatment.  825 
 826 
[H3] New Drugs  827 
An extensive pipeline of new therapeutics for ALS is available, and some of these drugs target known 828 
mutations and pathogenetic pathways.  Symptomatic therapies including tirazemptiv based on 829 
improving respiratory function in patients with ALS are currently in Phase 3 trials and exciting Phase I 830 
trials  assessing the use of antisense oligonucleotides in SOD1 and C9orf72 [related ALS are underway. In 831 
the future, treatments are likely to be targeted at specific subgroups of patients and biomarkers that are 832 
personalized to the individual disease subtype and have been developed from patient subcohorts that 833 
have been extensively phenotyped and stratified using genomics, transcriptomics, metabolomics and 834 
advanced imaging and signal analysis.  835 
 836 
 837 
  838 
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Display items 839 
 840 
Box 1. Mechanisms of SOD1 toxicity in cellular and rodent models  841 
Transgenic mice with mutations in SOD1 (encoding superoxide dismutase, SOD1  ) can be used to study 842 
ALS pathophysiology. These mice over-express mutant SOD1 and many have an aggressive disease 843 
course over approximately 80-90 days. However, they display quite well clinical and pathological 844 
features similar to human ALS.   845 
 SOD1 mutations can drive neurotoxicity in several ways, including protein misfolding [proteasome 846 
impairment, excitotoxicity, oxidative stress, ER stress, impaired axonal transport, axonopathy, 847 
inflammation, altered RNA processing and mitochondrial dysfunction. 232 Other mechanisms of SOD1-848 
related neurotoxicity have recently emerged and have gained interest.  SOD1 can acts as a transcription 849 
factor for genes involved in resistance to oxidative stress  and repair of oxidative damage  233.  RNA 850 
oxidation is emerging as a prominent pathological outcome of generalized oxidative stress in the cell 851 
with increasing importance in neurodegeneration  Astrocytes and oligodendrocytes reprogrammed from 852 
fibroblasts of patient with SOD1 mutations have been shown to induce hyperexcitability and cell death  853 
in healthy control motor neurons. Glial toxicity is mediated through both contact (lactate independent) 854 
and soluble mechanisms and is rescued by SOD1 knockdown using short hairpin RNA  in glia derived 855 
from patients with AOS1-related familial ALS, but also in glia derived from patients with sporadic ALS 856 
without SOD1 mutation 113.  Wild-type and mutant SOD1 proteins form insoluble  intraneuronal fibrils, 857 
which aggregate with increased propensity in the mutant form. A prion-like transmission of mutant 858 
SOD1 fibrils can seed wild-type SOD1 protein aggregation in neighbouring neurons and propagate 859 
neuronal injury234. 860 
Box 2. El Escorial criteria. 861 
 862 
  863 
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Figure 1. Clinical manifestations of ALS  864 
 Although motor manifestations such as muscle weakness and difficulty swallowing are the main clinical 865 
manifestations of amyotrophic lateral sclerosis, up to half of patients have non-motor symptoms, such 866 
as cognitive defects. 867 
Figure 2. Histopathology of ALS. 868 
a) Normal localization of TDP-43  in the nucleus (black arrow head), and aberrant localisation in a 869 
ĚŝƐĞĂƐĞĚŶĞƵƌŽŶǁŝƚŚůŽƐƐŽĨŶƵĐůĞĂƌĞǆƉƌĞƐƐŝŽŶĂŶĚĂ ?ƐŬĞŝŶ-ůŝŬĞ ?ŝŶĐůƵƐŝŽŶŝŶƚŚĞĐǇƚŽƉůĂƐŵ ?ďůĂĐŬ870 
arrow). b) Normal motor neuron (black arrow) and a hyaline conglomerate inclusion that stains for 871 
SMI31 (black arrow head) in a patient with ALS caused by a SOD1 mutation. c) TDP-43-negative, p62 872 
positive ĚŝƉĞƉƚŝĚĞƌĞƉĞĂƚŝŶĐůƵƐŝŽŶƐǁŝƚŚĂ ?ƐƚĞůůĂƚĞ ?ŵŽƌƉŚŽůŽŐǇŝŶ ƚŚĞƉǇƌĂŵŝĚĂůĐĞůůƐŽĨ ? ?ďůĂĐŬ873 
arrow) and granule cells of the dentate fascia (black arrow head) in the hippocampus of a patient with 874 
ALS caused by a mutation in C9orf72.  d) The spinal cord ventral horn of a patient with ALS and a  875 
healthy individual (e) showing a depleted numbers  of motor neurons in ALS (arrows).  F) CD68 (a 876 
microglial marker) immunohistochemistry shows marked microglial reactivity in the lateral tracts (black 877 
arrow) and ventral horns (black arrowhead), with no labelling  in the dorsal columns (white arrow).  878 
 879 
 880 
Figure 3. Pathophysiology of ALS . 881 
Mutations in several amyotrophic lateral sclerosis (ALS) causative genes  can exert motor neuronal injury 882 
through more than one pathophysiological mechanism, although these mechanisms are often 883 
interlinked. SOD1 is the longest studied gene implicated in ALS and has been linked to the most 884 
pathophysiological mechanisms, although the effects of mutations in  ALS3 and ALS7 are still unknown. 885 
Aberrant RNA metabolism and impaired protein homeostasis are predominant factors linking multiple 886 
ALS causative genes to neuronal injury. Mitochondrial dysfunction can arise from a mutation in 887 
CHCHD10 and from secondary respiratory chain deficiencies that arise from protein aggregates 888 
generated in the presence of other ALS genetic mutations  Both cases lead to an increase in oxidative 889 
stress, which puts further stress on an already impaired protein homeostasis system. Other mechanisms 890 
of ALS can directly alter neuronal function (such as nuclear export, impaired DNA repair, dysregulated 891 
vesicle transport and axon dysfunction) and the function of non-neuronal glial cells. The interplay of 892 
mechanisms is indicated by arrows. 893 
 894 
Figure 4. Staging systems for ALS. 895 
dŚĞ<ŝŶŐ ?ƐƐƚĂŐŝŶŐƐǇƐƚĞŵŝƐďĂƐĞĚŽŶƚŚĞŶƵŵďĞƌŽĨďŽĚǇƌĞŐŝŽŶƐĂĨĨĞĐƚĞĚďǇ>^ĂŶĚƚŚĞƉƌĞƐĞŶĐĞŽĨ896 
respiratory or nutritional failure  162. The Milano-Torino staging  (MITOS) system is based on the ALS 897 
functional rating scale (ALSFRS-R), a 48 point clinical measurement scale that records changes in bulbar, 898 
gross motor, fine motor and respiratory parameters 163. These staging systems do not incorporate 899 
cognitive or behavioural changes. The King ?s staging system is sensitive to early changes in ALS, but the 900 
sensitivity of the MITOS scale is greater in the later stages of disease 164, 165.  901 
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 903 
Figure 5. Factors affecting QOL  in patients with ALS. 904 
Several factors that positively or negatively affect overall quality of life (QOL) and health-related QOL 905 
(HRQOL) have been identified in patients with amyotrophic lateral sclerosis. These factors include motor 906 
symptoms, psychological symptoms and therapeutic interventions. AAC, augmentative and assistive 907 
communication; VC, verbal communication. 908 
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Table 1. Genes implicated in ALS.  911 
Gene 
locus  
 Gene (protein)  Inheritance Implicated disease 
mechanisms 
References 
ALS1  SOD1 (Superoxide dismutase 
1) 
AD/AR Oxidative stress 235, 236 
ALS2  ALS2 (Alsin)  AR  Endosomal 
trafficking 
237, 238 
ALS3  Unknown AD Unknown 239 
ALS4  SETX (Senataxin)  AD RNA metabolism  240 
ALS5  Unknown AR DNA damage 
repair, axon 
growth 
241 
ALS6  FUS/TLS (Fused in 
sarcoma/translated in 
liposarcoma)  
AD/AR RNA metabolism 242, 243 
ALS7  Unknown AD Unknown 244 
ALS8  VAPB (Vesicle associated 
membrane protein (VAMP)  ? 
associated protein B)[Au: 
should this be split up into 
two rows? Have VAMP and 
VAPB both been implicated 
in ALS?]  
AD ER stress 42 
ALS9  ANG (Angiogenin)  AD RNA metabolism  245 
ALS10  TARDBP (TAR DNA binding 
protein) 
AD RNA metabolism 27, 246 
ALS11  FIG4 (Polyphosphoinositide 
5-phosphatase  
AD Endosomal 
trafficking 
247 
ALS12  OPTN (Optineurin) AD/AR Autophagy 248 
ALS13  ATXN2 (Ataxin 2) AD RNA metabolism 249 
ALS14  VCP (Valosin-containing 
protein) 
AD Autophagy 36 
ALS15  UBQLN2 (Ubiquilin 2) XD UPS, autophagy  34 
ALS16  SIGMAR1 (Sigma non-opioid 
intracellular receptor 1) 
AD UPS, autophagy 250, 251 
ALS17  CHMP2B (Charged 
multivesicular body protein 
2B) 
AD Endosomal 
trafficking 
252 
ALS18  PFN1 (Profilin 1) AD Cytoskeleton 97 
ALS19  ERBB4 (V-erb-b2 avian 
erythroblastic leukaemia 
viral oncogene homolog 4) 
AD Neuronal 
development  
253 
ALS20  HNRNPA1 (Heterogeneous AD RNA metabolism  82 
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nuclear ribonucleoprotein 
A1) 
ALS21  MATR3 (Matrin 3) AD RNA metabolism 83 
ALS22  TUBA4A (Tubulin alpha-4A)   AD Cytoskeleton 102 
ALS-
FTD1 
 C9orf72 (Chromosome 9 
open reading frame 72) 
AD RNA metabolism, 
autophagy 
5, 6 
ALS-
FTD2 
 CHCHD10 (Coiled-coil-helix-
coiled-coil-helix domain 
containing 10) 
AD Mitochondrial 
maintenance  
255 
ALS-
FTD3 
 SQSTM1 (Sequestosome 1) AD Autophagy 256 
ALS-
FTD4 
  TBK1 (TANK-binding kinase 
1) 
  53, 54 
AD, autosomal dominant; AR, autosomal recessive; XD, X-linked dominant 912 
 913 
 914 
  915 
  33 
References  916 
1. Al-Chalabi, A., van den Berg, L.H. & Veldink, J. Gene discovery in amyotrophic lateral sclerosis: 917 
implications for clinical management. Nat Rev Neurol 13, 96-104 (2017). 918 
2. Phukan, J. et al. The syndrome of cognitive impairment in amyotrophic lateral sclerosis: a 919 
population-based study. J Neurol Neurosurg Psychiatry 83, 102-8 (2012). 920 
3. Elamin, M. et al. Cognitive changes predict functional decline in ALS: a population-based 921 
longitudinal study. Neurology 80, 1590-7 (2013). 922 
4. Neumann, M. et al. Ubiquitinated TDP-43 in frontotemporal lobar degeneration and 923 
amyotrophic lateral sclerosis. Science 314, 130-3 (2006). 924 
5. DeJesus-Hernandez, M. et al. Expanded GGGGCC hexanucleotide repeat in noncoding region of 925 
C9ORF72 causes chromosome 9p-linked FTD and ALS. Neuron 72, 245-56 (2011). 926 
6. Renton, A.E. et al. A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 927 
9p21-linked ALS-FTD. Neuron 72, 257-68 (2011). 928 
7. Al-Chalabi, A. et al. Amyotrophic lateral sclerosis: moving towards a new classification system. 929 
Lancet Neurol 15, 1182-94 (2016). 930 
8. Rooney, J.P.K. et al. Benefits, pitfalls, and future design of population-based registers in 931 
neurodegenerative disease. Neurology 88, 2321-2329 (2017). 932 
9. Logroscino, G. et al. Incidence of amyotrophic lateral sclerosis in Europe. J Neurol Neurosurg 933 
Psychiatry 81, 385-90 (2010). 934 
10. Hardiman, O. et al. The changing picture of amyotrophic lateral sclerosis: lessons from European 935 
registers. J Neurol Neurosurg Psychiatry (2017). 936 
11. Chio, A. et al. Global epidemiology of amyotrophic lateral sclerosis: a systematic review of the 937 
published literature. Neuroepidemiology 41, 118-30 (2013). 938 
12. Marin, B. et al. Population-based epidemiology of amyotrophic lateral sclerosis (ALS) in an 939 
ageing Europe--the French register of ALS in Limousin (FRALim register). Eur J Neurol 21, 1292-940 
300, e78-9 (2014). 941 
13. Gordon, P.H. et al. Incidence of amyotrophic lateral sclerosis among American Indians and 942 
Alaska natives. JAMA Neurol 70, 476-80 (2013). 943 
14. Joensen, P. Incidence of amyotrophic lateral sclerosis in the Faroe Islands. Acta Neurol Scand 944 
126, 62-6 (2012). 945 
15. Marin, B. et al. Clinical and demographic factors and outcome of amyotrophic lateral sclerosis in 946 
relation to population ancestral origin. Eur J Epidemiol 31, 229-45 (2016). 947 
16. Zaldivar, T. et al. Reduced frequency of ALS in an ethnically mixed population: a population-948 
based mortality study. Neurology 72, 1640-5 (2009). 949 
17. Heiman-Patterson, T.D. et al. Genetic background effects on disease onset and lifespan of the 950 
mutant dynactin p150Glued mouse model of motor neuron disease. PLoS One 10, e0117848 951 
(2015). 952 
18. Heiman-Patterson, T.D. et al. Effect of genetic background on phenotype variability in transgenic 953 
mouse models of amyotrophic lateral sclerosis: a window of opportunity in the search for 954 
genetic modifiers. Amyotroph Lateral Scler 12, 79-86 (2011). 955 
19. van Rheenen, W. et al. Genome-wide association analyses identify new risk variants and the 956 
genetic architecture of amyotrophic lateral sclerosis. Nature Genetics 48, 1043-8 (2016). 957 
20. Chio, A. et al. Genetic counselling in ALS: facts, uncertainties and clinical suggestions. J Neurol 958 
Neurosurg Psychiatry 85, 478-85 (2014). 959 
21. van Blitterswijk, M. et al. Evidence for an oligogenic basis of amyotrophic lateral sclerosis. Hum 960 
Mol Genet 21, 3776-84 (2012). 961 
  34 
22. Renton, A.E., Chio, A. & Traynor, B.J. State of play in amyotrophic lateral sclerosis genetics. Nat 962 
Neurosci 17, 17-23 (2014). 963 
23. Steele, J.C. & McGeer, P.L. The ALS/PDC syndrome of Guam and the cycad hypothesis. 964 
Neurology 70, 1984-90 (2008). 965 
24. Bradley, W.G. et al. Is exposure to cyanobacteria an environmental risk factor for amyotrophic 966 
lateral sclerosis and other neurodegenerative diseases? Amyotroph Lateral Scler Frontotemporal 967 
Degener 14, 325-33 (2013). 968 
25. Rooney, J.P.K. et al. Euro-MOTOR; A case control-study of hormonal exposures as etiological 969 
factors for ALS in women. Neurology (In Press). 970 
26. Wang, M.D., Little, J., Gomes, J., Cashman, N.R. & Krewski, D. Identification of risk factors 971 
associated with onset and progression of amyotrophic lateral sclerosis using systematic review 972 
and meta-analysis. Neurotoxicology (2016). 973 
27. Kabashi, E. et al. TARDBP mutations in individuals with sporadic and familial amyotrophic lateral 974 
sclerosis. Nat Genet 40, 572-4 (2008). 975 
28. Van Deerlin, V.M. et al. TARDBP mutations in amyotrophic lateral sclerosis with TDP-43 976 
neuropathology: a genetic and histopathological analysis. Lancet Neurol 7, 409-16 (2008). 977 
29. Ross, C.A. & Poirier, M.A. Opinion: What is the role of protein aggregation in 978 
neurodegeneration? Nat Rev Mol Cell Biol 6, 891-8 (2005). 979 
30. Marino, M. et al. Differences in protein quality control correlate with phenotype variability in 2 980 
mouse models of familial amyotrophic lateral sclerosis. Neurobiol Aging 36, 492-504 (2015). 981 
31. Aguzzi, A. & Rajendran, L. The transcellular spread of cytosolic amyloids, prions, and prionoids. 982 
Neuron 64, 783-90 (2009). 983 
32. Polymenidou, M. & Cleveland, D.W. The seeds of neurodegeneration: prion-like spreading in 984 
ALS. Cell 147, 498-508 (2011). 985 
33. Urushitani, M., Kurisu, J., Tsukita, K. & Takahashi, R. Proteasomal inhibition by misfolded mutant 986 
superoxide dismutase 1 induces selective motor neuron death in familial amyotrophic lateral 987 
sclerosis. J Neurochem 83, 1030-42 (2002). 988 
34. Deng, H.X. et al. Mutations in UBQLN2 cause dominant X-linked juvenile and adult-onset ALS 989 
and ALS/dementia. Nature 477, 211-5 (2011). 990 
35. Chang, L. & Monteiro, M.J. Defective Proteasome Delivery of Polyubiquitinated Proteins by 991 
Ubiquilin-2 Proteins Containing ALS Mutations. PLoS One 10, e0130162 (2015). 992 
36. Johnson, J.O. et al. Exome sequencing reveals VCP mutations as a cause of familial ALS. Neuron 993 
68, 857-64 (2010). 994 
37. Gaastra, B. et al. Rare genetic variation in UNC13A may modify survival in amyotrophic lateral 995 
sclerosis. Amyotroph Lateral Scler Frontotemporal Degener 17, 593-599 (2016). 996 
38. Basso, M. et al. Characterization of detergent-insoluble proteins in ALS indicates a causal link 997 
between nitrative stress and aggregation in pathogenesis. PLoS One 4, e8130 (2009). 998 
39. Chang, H.Y., Hou, S.C., Way, T.D., Wong, C.H. & Wang, I.F. Heat-shock protein dysregulation is 999 
associated with functional and pathological TDP-43 aggregation. Nat Commun 4, 2757 (2013). 1000 
40. Bergemalm, D. et al. Superoxide dismutase-1 and other proteins in inclusions from transgenic 1001 
amyotrophic lateral sclerosis model mice. J Neurochem 114, 408-18 (2010). 1002 
41. Chen, H.J. et al. Characterization of the properties of a novel mutation in VAPB in familial 1003 
amyotrophic lateral sclerosis. J Biol Chem 285, 40266-81 (2010). 1004 
42. Nishimura, A.L. et al. A mutation in the vesicle-trafficking protein VAPB causes late-onset spinal 1005 
muscular atrophy and amyotrophic lateral sclerosis. Am J Hum Genet 75, 822-31 (2004). 1006 
43. Webster, C.P., Smith, E.F., Bauer, C.S., Moller, A. & Hautbergue, G.M. The C9orf72 protein 1007 
interacts with Rab1a and the ULK1 complex to regulate initiation of autophagy. Embo j 35, 1656-1008 
76 (2016). 1009 
  35 
44. Katsuragi, Y., Ichimura, Y. & Komatsu, M. p62/SQSTM1 functions as a signaling hub and an 1010 
autophagy adaptor. Febs j 282, 4672-8 (2015). 1011 
45. Wong, Y.C. & Holzbaur, E.L. Optineurin is an autophagy receptor for damaged mitochondria in 1012 
parkin-mediated mitophagy that is disrupted by an ALS-linked mutation. Proc Natl Acad Sci U S A 1013 
111, E4439-48 (2014). 1014 
46. Hjerpe, R. et al. UBQLN2 Mediates Autophagy-Independent Protein Aggregate Clearance by the 1015 
Proteasome. Cell 166, 935-49 (2016). 1016 
47. Ferguson, C.J., Lenk, G.M. & Meisler, M.H. Defective autophagy in neurons and astrocytes from 1017 
mice deficient in PI(3,5)P2. Hum Mol Genet 18, 4868-78 (2009). 1018 
48. Hadano, S. et al. Functional links between SQSTM1 and ALS2 in the pathogenesis of ALS: 1019 
cumulative impact on the protection against mutant SOD1-mediated motor dysfunction in mice. 1020 
Hum Mol Genet 25, 3321-3340 (2016). 1021 
49. Hadano, S. et al. Loss of ALS2/Alsin exacerbates motor dysfunction in a SOD1-expressing mouse 1022 
ALS model by disturbing endolysosomal trafficking. PLoS One 5, e9805 (2010). 1023 
50. Otomo, A., Pan, L. & Hadano, S. Dysregulation of the autophagy-endolysosomal system in 1024 
amyotrophic lateral sclerosis and related motor neuron diseases. Neurol Res Int 2012, 498428 1025 
(2012). 1026 
51. Ju, J.S. et al. Valosin-containing protein (VCP) is required for autophagy and is disrupted in VCP 1027 
disease. J Cell Biol 187, 875-88 (2009). 1028 
52. Goode, A. et al. Defective recognition of LC3B by mutant SQSTM1/p62 implicates impairment of 1029 
autophagy as a pathogenic mechanism in ALS-FTLD. Autophagy 12, 1094-104 (2016). 1030 
53. Weidberg, H. & Elazar, Z. TBK1 mediates crosstalk between the innate immune response and 1031 
autophagy. Sci Signal 4, pe39 (2011). 1032 
54. Matsumoto, G., Shimogori, T., Hattori, N. & Nukina, N. TBK1 controls autophagosomal 1033 
engulfment of polyubiquitinated mitochondria through p62/SQSTM1 phosphorylation. Hum Mol 1034 
Genet 24, 4429-42 (2015). 1035 
55. Topp, J.D., Gray, N.W., Gerard, R.D. & Horazdovsky, B.F. Alsin is a Rab5 and Rac1 guanine 1036 
nucleotide exchange factor. J Biol Chem 279, 24612-23 (2004). 1037 
56. Pasquali, L., Lenzi, P., Biagioni, F., Siciliano, G. & Fornai, F. Cell to cell spreading of misfolded 1038 
proteins as a therapeutic target in motor neuron disease. Curr Med Chem 21, 3508-34 (2014). 1039 
57. Conicella, A.E., Zerze, G.H., Mittal, J. & Fawzi, N.L. ALS Mutations Disrupt Phase Separation 1040 
Mediated by alpha-Helical Structure in the TDP-43 Low-Complexity C-Terminal Domain. 1041 
Structure 24, 1537-49 (2016). 1042 
58. Zhou, Y., Liu, S., Ozturk, A. & Hicks, G.G. FUS-regulated RNA metabolism and DNA damage 1043 
repair: Implications for amyotrophic lateral sclerosis and frontotemporal dementia 1044 
pathogenesis. Rare Dis 2, e29515 (2014). 1045 
59. Amlie-Wolf, A. et al. Transcriptomic Changes Due to Cytoplasmic TDP-43 Expression Reveal 1046 
Dysregulation of Histone Transcripts and Nuclear Chromatin. PLoS One 10, e0141836 (2015). 1047 
60. Arnold, E.S. et al. ALS-linked TDP-43 mutations produce aberrant RNA splicing and adult-onset 1048 
motor neuron disease without aggregation or loss of nuclear TDP-43. Proc Natl Acad Sci U S A 1049 
110, E736-45 (2013). 1050 
61. Walsh, M.J. et al. Invited review: decoding the pathophysiological mechanisms that underlie 1051 
RNA dysregulation in neurodegenerative disorders: a review of the current state of the art. 1052 
Neuropathol Appl Neurobiol 41, 109-34 (2015). 1053 
62. Chen-Plotkin, A.S., Lee, V.M. & Trojanowski, J.Q. TAR DNA-binding protein 43 in 1054 
neurodegenerative disease. Nat Rev Neurol 6, 211-20 (2010). 1055 
63. Ratti, A. & Buratti, E. Physiological functions and pathobiology of TDP-43 and FUS/TLS proteins. J 1056 
Neurochem 138 Suppl 1, 95-111 (2016). 1057 
  36 
64. Haeusler, A.R. et al. C9orf72 nucleotide repeat structures initiate molecular cascades of disease. 1058 
Nature 507, 195-200 (2014). 1059 
65. Reddy, K., Zamiri, B., Stanley, S.Y., Macgregor, R.B., Jr. & Pearson, C.E. The disease-associated 1060 
r(GGGGCC)n repeat from the C9orf72 gene forms tract length-dependent uni- and 1061 
multimolecular RNA G-quadruplex structures. J Biol Chem 288, 9860-6 (2013). 1062 
66. Lee, Y.B. et al. Hexanucleotide repeats in ALS/FTD form length-dependent RNA foci, sequester 1063 
RNA binding proteins, and are neurotoxic. Cell Rep 5, 1178-86 (2013). 1064 
67. Donnelly, C.J. et al. RNA toxicity from the ALS/FTD C9ORF72 expansion is mitigated by antisense 1065 
intervention. Neuron 80, 415-28 (2013). 1066 
68. Cooper-Knock, J. et al. Sequestration of multiple RNA recognition motif-containing proteins by 1067 
C9orf72 repeat expansions. Brain 137, 2040-51 (2014). 1068 
69. Cooper-Knock, J. et al. C9ORF72 GGGGCC Expanded Repeats Produce Splicing Dysregulation 1069 
which Correlates with Disease Severity in Amyotrophic Lateral Sclerosis. PLoS One 10, e0127376 1070 
(2015). 1071 
70. Haeusler, A.R., Donnelly, C.J. & Rothstein, J.D. The expanding biology of the C9orf72 nucleotide 1072 
repeat expansion in neurodegenerative disease. Nat Rev Neurosci 17, 383-95 (2016). 1073 
71. Santos-Pereira, J.M. & Aguilera, A. R loops: new modulators of genome dynamics and function. 1074 
Nat Rev Genet 16, 583-97 (2015). 1075 
72. Walker, C. et al. C9orf72 expansion disrupts ATM-mediated chromosomal break repair.  (2017). 1076 
73. Chan, Y.A., Hieter, P. & Stirling, P.C. Mechanisms of genome instability induced by RNA-1077 
processing defects. Trends Genet 30, 245-53 (2014). 1078 
74. Skourti-Stathaki, K., Proudfoot, N.J. & Gromak, N. Human senataxin resolves RNA/DNA hybrids 1079 
formed at transcriptional pause sites to promote Xrn2-dependent termination. Mol Cell 42, 794-1080 
805 (2011). 1081 
75. Pizzo, E. et al. Ribonuclease/angiogenin inhibitor 1 regulates stress-induced subcellular 1082 
localization of angiogenin to control growth and survival. Journal of Cell Science 126, 4308-4319 1083 
(2013). 1084 
76. Saxena, S.K., Rybak, S.M., Davey, R.T., Youle, R.J. & Ackerman, E.J. Angiogenin Is a Cytotoxic, 1085 
Transfer Rna-Specific Ribonuclease in the Rnase-a Superfamily. Journal of Biological Chemistry 1086 
267, 21982-21986 (1992). 1087 
77. Simpson, C.L. et al. Variants of the elongator protein 3 (ELP3) gene are associated with motor 1088 
neuron degeneration. Hum Mol Genet 18, 472-81 (2009). 1089 
78. Kapeli, K. et al. Distinct and shared functions of ALS-associated proteins TDP-43, FUS and TAF15 1090 
revealed by multisystem analyses. Nat Commun 7, 12143 (2016). 1091 
79. Couthouis, J. et al. Evaluating the role of the FUS/TLS-related gene EWSR1 in amyotrophic lateral 1092 
sclerosis. Hum Mol Genet 21, 2899-911 (2012). 1093 
80. Han, Q.J. et al. Gcn5- and Elp3-induced histone H3 acetylation regulates hsp70 gene 1094 
transcription in yeast. Biochemical Journal 409, 779-788 (2008). 1095 
81. Huang, B., Johansson, M.J.O. & Bystrom, A.S. An early step in wobble uridine tRNA modification 1096 
requires the Elongator complex. Rna-a Publication of the Rna Society 11, 424-436 (2005). 1097 
82. Kim, H.J. et al. Mutations in prion-like domains in hnRNPA2B1 and hnRNPA1 cause multisystem 1098 
proteinopathy and ALS. Nature 495, 467-73 (2013). 1099 
83. Johnson, J.O. et al. Mutations in the Matrin 3 gene cause familial amyotrophic lateral sclerosis. 1100 
Nat Neurosci 17, 664-6 (2014). 1101 
84. Vanderweyde, T., Youmans, K., Liu-Yesucevitz, L. & Wolozin, B. Role of stress granules and RNA-1102 
binding proteins in neurodegeneration: a mini-review. Gerontology 59, 524-33 (2013). 1103 
  37 
85. Winton, M.J. et al. Disturbance of nuclear and cytoplasmic TAR DNA-binding protein (TDP-43) 1104 
induces disease-like redistribution, sequestration, and aggregate formation. J Biol Chem 283, 1105 
13302-9 (2008). 1106 
86. Parker, S.J. et al. Endogenous TDP-43 localized to stress granules can subsequently form protein 1107 
aggregates. Neurochem Int 60, 415-24 (2012). 1108 
87. Zhang, K. et al. The C9orf72 repeat expansion disrupts nucleocytoplasmic transport. Nature 525, 1109 
56-61 (2015). 1110 
88. Freibaum, B.D. et al. GGGGCC repeat expansion in C9orf72 compromises nucleocytoplasmic 1111 
transport. Nature 525, 129-33 (2015). 1112 
89. Boeynaems, S. et al. Phase Separation of C9orf72 Dipeptide Repeats Perturbs Stress Granule 1113 
Dynamics. Mol Cell 65, 1044-1055.e5 (2017). 1114 
90. Walsh, M.J., Hautbergue, G.M. & Wilson, S.A. Structure and function of mRNA export adaptors. 1115 
Biochem Soc Trans 38, 232-6 (2010). 1116 
91. Hautbergue, G.M., Castelli, L.M., Ferraiuolo, L. & Sanchez-Martinez, A. SRSF1-dependent nuclear 1117 
export inhibition of C9ORF72 repeat transcripts prevents neurodegeneration and associated 1118 
motor deficits.  8, 16063 (2017). 1119 
92. Schwenk, B.M. et al. TDP-43 loss of function inhibits endosomal trafficking and alters trophic 1120 
signaling in neurons. Embo j 35, 2350-2370 (2016). 1121 
93. Devon, R.S. et al. Als2-deficient mice exhibit disturbances in endosome trafficking associated 1122 
with motor behavioral abnormalities. Proc Natl Acad Sci U S A 103, 9595-600 (2006). 1123 
94. Bohme, M.A. et al. Active zone scaffolds differentially accumulate Unc13 isoforms to tune Ca(2+) 1124 
channel-vesicle coupling. Nat Neurosci 19, 1311-20 (2016). 1125 
95. Smith, B.N. et al. Exome-wide rare variant analysis identifies TUBA4A mutations associated with 1126 
familial ALS. Neuron 84, 324-31 (2014). 1127 
96. Puls, I. et al. Mutant dynactin in motor neuron disease. Nat Genet 33, 455-6 (2003). 1128 
97. Wu, C.H. et al. Mutations in the profilin 1 gene cause familial amyotrophic lateral sclerosis. 1129 
Nature 488, 499-503 (2012). 1130 
98. Garcia, M.L. et al. Mutations in neurofilament genes are not a significant primary cause of non-1131 
SOD1-mediated amyotrophic lateral sclerosis. Neurobiol Dis 21, 102-9 (2006). 1132 
99. Gros-Louis, F. et al. A frameshift deletion in peripherin gene associated with amyotrophic lateral 1133 
sclerosis. J Biol Chem 279, 45951-6 (2004). 1134 
100. Corrado, L. et al. A novel peripherin gene (PRPH) mutation identified in one sporadic 1135 
amyotrophic lateral sclerosis patient. Neurobiol Aging 32, 552.e1-6 (2011). 1136 
101. Wang, W.Y. et al. Interaction of FUS and HDAC1 regulates DNA damage response and repair in 1137 
neurons. Nat Neurosci 16, 1383-91 (2013). 1138 
102. Sama, R.R., Ward, C.L. & Bosco, D.A. Functions of FUS/TLS from DNA repair to stress response: 1139 
implications for ALS. ASN Neuro 6 (2014). 1140 
103. Kenna, K.P. et al. NEK1 variants confer susceptibility to amyotrophic lateral sclerosis. Nature 1141 
Genetics 48, 1037-+ (2016). 1142 
104. Fang, X. et al. The NEK1 interactor, C21ORF2, is required for efficient DNA damage repair. Acta 1143 
Biochim Biophys Sin (Shanghai) 47, 834-41 (2015). 1144 
105. van Rheenen, W. et al. Genome-wide association analyses identify new risk variants and the 1145 
genetic architecture of amyotrophic lateral sclerosis. Nat Genet 48, 1043-8 (2016). 1146 
106. Laslo, P., Lipski, J., Nicholson, L.F., Miles, G.B. & Funk, G.D. GluR2 AMPA receptor subunit 1147 
expression in motoneurons at low and high risk for degeneration in amyotrophic lateral 1148 
sclerosis. Exp Neurol 169, 461-71 (2001). 1149 
  38 
107. Wang, S.J., Wang, K.Y. & Wang, W.C. Mechanisms underlying the riluzole inhibition of glutamate 1150 
release from rat cerebral cortex nerve terminals (synaptosomes). Neuroscience 125, 191-201 1151 
(2004). 1152 
108. Kretschmer, B.D., Kratzer, U. & Schmidt, W.J. Riluzole, a glutamate release inhibitor, and motor 1153 
behavior. Naunyn-Schmiedebergs Archives of Pharmacology 358, 181-190 (1998). 1154 
109. Kang, S.H. et al. Degeneration and impaired regeneration of gray matter oligodendrocytes in 1155 
amyotrophic lateral sclerosis. Nat Neurosci 16, 571-9 (2013). 1156 
110. Philips, T. et al. Oligodendrocyte dysfunction in the pathogenesis of amyotrophic lateral 1157 
sclerosis. Brain 136, 471-82 (2013). 1158 
111. Rinholm, J.E. et al. Regulation of oligodendrocyte development and myelination by glucose and 1159 
lactate. J Neurosci 31, 538-48 (2011). 1160 
112. Lee, Y. et al. Oligodendroglia metabolically support axons and contribute to neurodegeneration. 1161 
Nature 487, 443-8 (2012). 1162 
113. Ferraiuolo, L. et al. Oligodendrocytes contribute to motor neuron death in ALS via SOD1-1163 
dependent mechanism. Proc Natl Acad Sci U S A 113, E6496-e6505 (2016). 1164 
114. Corcia, P. et al. Molecular imaging of microglial activation in amyotrophic lateral sclerosis. PLoS 1165 
One 7, e52941 (2012). 1166 
115. Brites, D. & Vaz, A.R. Microglia centered pathogenesis in ALS: insights in cell interconnectivity. 1167 
Front Cell Neurosci 8, 117 (2014). 1168 
116. Wang, L., Gutmann, D.H. & Roos, R.P. Astrocyte loss of mutant SOD1 delays ALS disease onset 1169 
and progression in G85R transgenic mice. Hum Mol Genet 20, 286-93 (2011). 1170 
117. Liao, B., Zhao, W., Beers, D.R., Henkel, J.S. & Appel, S.H. Transformation from a neuroprotective 1171 
to a neurotoxic microglial phenotype in a mouse model of ALS. Exp Neurol 237, 147-52 (2012). 1172 
118. Vande Velde, C. et al. Misfolded SOD1 associated with motor neuron mitochondria alters 1173 
mitochondrial shape and distribution prior to clinical onset. PLoS One 6, e22031 (2011). 1174 
119. Magrane, J., Cortez, C., Gan, W.B. & Manfredi, G. Abnormal mitochondrial transport and 1175 
morphology are common pathological denominators in SOD1 and TDP43 ALS mouse models. 1176 
Hum Mol Genet 23, 1413-24 (2014). 1177 
120. Higgins, C.M., Jung, C. & Xu, Z. ALS-associated mutant SOD1G93A causes mitochondrial 1178 
vacuolation by expansion of the intermembrane space and by involvement of SOD1 aggregation 1179 
and peroxisomes. BMC Neurosci 4, 16 (2003). 1180 
121. Parone, P.A. et al. Enhancing mitochondrial calcium buffering capacity reduces aggregation of 1181 
misfolded SOD1 and motor neuron cell death without extending survival in mouse models of 1182 
inherited amyotrophic lateral sclerosis. J Neurosci 33, 4657-71 (2013). 1183 
122. Laird, F.M. et al. Motor neuron disease occurring in a mutant dynactin mouse model is 1184 
characterized by defects in vesicular trafficking. J Neurosci 28, 1997-2005 (2008). 1185 
123. Bilsland, L.G. et al. Deficits in axonal transport precede ALS symptoms in vivo. Proc Natl Acad Sci 1186 
U S A 107, 20523-8 (2010). 1187 
124. De Vos, K.J. et al. VAPB interacts with the mitochondrial protein PTPIP51 to regulate calcium 1188 
homeostasis. Hum Mol Genet 21, 1299-311 (2012). 1189 
125. Stoica, R. et al. ALS/FTD-associated FUS activates GSK-3beta to disrupt the VAPB-PTPIP51 1190 
interaction and ER-mitochondria associations. EMBO Rep 17, 1326-42 (2016). 1191 
126. Stoica, R. et al. ER-mitochondria associations are regulated by the VAPB-PTPIP51 interaction and 1192 
are disrupted by ALS/FTD-associated TDP-43. Nat Commun 5, 3996 (2014). 1193 
127. Wang, W. et al. The inhibition of TDP-43 mitochondrial localization blocks its neuronal toxicity. 1194 
Nat Med 22, 869-78 (2016). 1195 
  39 
128. Lopez-Gonzalez, R. et al. Poly(GR) in C9ORF72-Related ALS/FTD Compromises Mitochondrial 1196 
Function and Increases Oxidative Stress and DNA Damage in iPSC-Derived Motor Neurons. 1197 
Neuron 92, 383-391 (2016). 1198 
129. Genin, E.C. et al. CHCHD10 mutations promote loss of mitochondrial cristae junctions with 1199 
impaired mitochondrial genome maintenance and inhibition of apoptosis. EMBO Mol Med 8, 58-1200 
72 (2016). 1201 
130. Iyer, P.M. et al. Functional Connectivity Changes in Resting-State EEG as Potential Biomarker for 1202 
Amyotrophic Lateral Sclerosis. PLoS One 10, e0128682 (2015). 1203 
131. Hegedus, J., Putman, C.T., Tyreman, N. & Gordon, T. Preferential motor unit loss in the SOD1 1204 
G93A transgenic mouse model of amyotrophic lateral sclerosis. J Physiol 586, 3337-51 (2008). 1205 
132. Saxena, S. & Caroni, P. Selective neuronal vulnerability in neurodegenerative diseases: from 1206 
stressor thresholds to degeneration. Neuron 71, 35-48 (2011). 1207 
133. Tartaglia, M.C. et al. Differentiation between primary lateral sclerosis and amyotrophic lateral 1208 
sclerosis: examination of symptoms and signs at disease onset and during follow-up. Arch Neurol 1209 
64, 232-6 (2007). 1210 
134. Van den Berg-Vos, R.M. et al. A long-term prospective study of the natural course of sporadic 1211 
adult-onset lower motor neuron syndromes. Arch Neurol 66, 751-7 (2009). 1212 
135. Visser, J. et al. Disease course and prognostic factors of progressive muscular atrophy. Arch 1213 
Neurol 64, 522-8 (2007). 1214 
136. van den Berg-Vos, R.M. et al. Sporadic lower motor neuron disease with adult onset: 1215 
classification of subtypes. Brain 126, 1036-47 (2003). 1216 
137. Kiernan, M.C. et al. Amyotrophic lateral sclerosis. Lancet 377, 942-55 (2011). 1217 
138. Dupuis, L., Pradat, P.F., Ludolph, A.C. & Loeffler, J.P. Energy metabolism in amyotrophic lateral 1218 
sclerosis. Lancet Neurol 10, 75-82 (2011). 1219 
139. Moglia, C. et al. Influence of arterial hypertension, type 2 diabetes and cardiovascular risk 1220 
factors on ALS outcome: a population-based study. Amyotroph Lateral Scler Frontotemporal 1221 
Degener, 1-7 (2017). 1222 
140. Strong, M.J. et al. Amyotrophic lateral sclerosis - frontotemporal spectrum disorder (ALS-FTSD): 1223 
Revised diagnostic criteria. Amyotroph Lateral Scler Frontotemporal Degener, 1-22 (2017). 1224 
141. Burke, T. et al. A Cross-sectional population-based investigation into behavioral change in 1225 
amyotrophic lateral sclerosis: subphenotypes, staging, cognitive predictors, and survival. Ann 1226 
Clin Transl Neurol 4, 305-317 (2017). 1227 
142. Brooks, B.R., Miller, R.G., Swash, M. & Munsat, T.L. El Escorial revisited: revised criteria for the 1228 
diagnosis of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord 1229 
1, 293-9 (2000). 1230 
143. Reniers, W. et al. Prognostic value of clinical and electrodiagnostic parameters at time of 1231 
diagnosis in patients with amyotrophic lateral sclerosis. Amyotroph Lateral Scler Frontotemporal 1232 
Degener 18, 341-350 (2017). 1233 
144. Agosta, F. et al. The El Escorial criteria: strengths and weaknesses. Amyotroph Lateral Scler 1234 
Frontotemporal Degener 16, 1-7 (2015). 1235 
145. Ludolph, A. et al. A revision of the El Escorial criteria - 2015. Amyotroph Lateral Scler 1236 
Frontotemporal Degener 16, 291-2 (2015). 1237 
146. Byrne, S. et al. Proposed criteria for familial amyotrophic lateral sclerosis. Amyotroph Lateral 1238 
Scler 12, 157-9 (2011). 1239 
147. Vajda, A. et al. Genetic testing in ALS: A survey of current practices. Neurology 88, 991-999 1240 
(2017). 1241 
148. Abrahams, S., Newton, J., Niven, E., Foley, J. & Bak, T.H. Screening for cognition and behaviour 1242 
changes in ALS. Amyotroph Lateral Scler Frontotemporal Degener 15, 9-14 (2014). 1243 
  40 
149. Pinto-Grau, M. et al. Screening for cognitive dysfunction in ALS: validation of the Edinburgh 1244 
Cognitive and Behavioural ALS Screen (ECAS) using age and education adjusted normative data. 1245 
Amyotroph Lateral Scler Frontotemporal Degener 18, 99-106 (2017). 1246 
150. Burke, T., Elamin, M., Galvin, M., Hardiman, O. & Pender, N. Caregiver burden in amyotrophic 1247 
lateral sclerosis: a cross-sectional investigation of predictors. J Neurol 262, 1526-32 (2015). 1248 
151. Steinacker, P. et al. Neurofilaments in the diagnosis of motoneuron diseases: a prospective 1249 
study on 455 patients. J Neurol Neurosurg Psychiatry 87, 12-20 (2016). 1250 
152. Gaiottino, J. et al. Increased neurofilament light chain blood levels in neurodegenerative 1251 
neurological diseases. PLoS One 8, e75091 (2013). 1252 
153. Gaiani, A. et al. Diagnostic and Prognostic Biomarkers in Amyotrophic Lateral Sclerosis: 1253 
Neurofilament Light Chain Levels in Definite Subtypes of Disease. JAMA Neurol (2017). 1254 
154. Schuster, C., Elamin, M., Hardiman, O. & Bede, P. Presymptomatic and longitudinal 1255 
neuroimaging in neurodegeneration--from snapshots to motion picture: a systematic review. J 1256 
Neurol Neurosurg Psychiatry 86, 1089-96 (2015). 1257 
155. Bede, P. et al. The selective anatomical vulnerability of ALS: 'disease-defining' and 'disease-1258 
defying' brain regions. Amyotroph Lateral Scler Frontotemporal Degener 17, 561-570 (2016). 1259 
156. Bede, P. & Hardiman, O. Lessons of ALS imaging: Pitfalls and future directions - A critical review. 1260 
Neuroimage Clin 4, 436-43 (2014). 1261 
157. Canosa, A. et al. 18F-FDG-PET correlates of cognitive impairment in ALS. Neurology 86, 44-9 1262 
(2016). 1263 
158. Turner, M.R. et al. The diagnostic pathway and prognosis in bulbar-onset amyotrophic lateral 1264 
sclerosis. J Neurol Sci 294, 81-5 (2010). 1265 
159. Hanemann, C.O. & Ludolph, A.C. Hereditary motor neuropathies and motor neuron diseases: 1266 
which is which. Amyotroph Lateral Scler Other Motor Neuron Disord 3, 186-9 (2002). 1267 
160. Mastaglia, F.L. & Needham, M. Inclusion body myositis: a review of clinical and genetic aspects, 1268 
diagnostic criteria and therapeutic approaches. J Clin Neurosci 22, 6-13 (2015). 1269 
161. Traynor, B.J. et al. Amyotrophic lateral sclerosis mimic syndromes: a population-based study. 1270 
Arch Neurol 57, 109-13 (2000). 1271 
162. Balendra, R. et al. Estimating clinical stage of amyotrophic lateral sclerosis from the ALS 1272 
Functional Rating Scale. Amyotroph Lateral Scler Frontotemporal Degener 15, 279-84 (2014). 1273 
163. Chio, A., Hammond, E.R., Mora, G., Bonito, V. & Filippini, G. Development and evaluation of a 1274 
clinical staging system for amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry 86, 38-44 1275 
(2015). 1276 
164. Fang, T. et al. Comparison of the King's and MiToS staging systems for ALS. Amyotroph Lateral 1277 
Scler Frontotemporal Degener, 1-6 (2017). 1278 
165. Ferraro, D. et al. Amyotrophic lateral sclerosis: a comparison of two staging systems in a 1279 
population-based study. Eur J Neurol 23, 1426-32 (2016). 1280 
166. Elamin, M. et al. Predicting prognosis in amyotrophic lateral sclerosis: a simple algorithm. J 1281 
Neurol 262, 1447-54 (2015). 1282 
167. Hothorn, T. & Jung, H.H. RandomForest4Life: a Random Forest for predicting ALS disease 1283 
progression. Amyotroph Lateral Scler Frontotemporal Degener 15, 444-52 (2014). 1284 
168. Oh, S.I. et al. Prognostic Role of Serum Levels of Uric Acid in Amyotrophic Lateral Sclerosis. J Clin 1285 
Neurol 11, 376-82 (2015). 1286 
169. Chio, A. et al. Amyotrophic lateral sclerosis outcome measures and the role of albumin and 1287 
creatinine: a population-based study. JAMA Neurol 71, 1134-42 (2014). 1288 
170. Kori, M., Aydin, B., Unal, S., Arga, K.Y. & Kazan, D. Metabolic Biomarkers and 1289 
Neurodegeneration: A Pathway Enrichment Analysis of Alzheimer's Disease, Parkinson's Disease, 1290 
and Amyotrophic Lateral Sclerosis. Omics 20, 645-661 (2016). 1291 
  41 
171. Pinto, S. & de Carvalho, M. Correlation between Forced Vital Capacity and Slow Vital Capacity 1292 
for the assessment of respiratory involvement in Amyotrophic Lateral Sclerosis: a prospective 1293 
study. Amyotroph Lateral Scler Frontotemporal Degener 18, 86-91 (2017). 1294 
172. Morgan, R.K. et al. Use of Sniff nasal-inspiratory force to predict survival in amyotrophic lateral 1295 
sclerosis. Am J Respir Crit Care Med 171, 269-74 (2005). 1296 
173. Roggenbuck, J. & Quick, A. Genetic testing and genetic counseling for amyotrophic lateral 1297 
sclerosis: an update for clinicians. Genet Med 19, 267-274 (2017). 1298 
174. Benatar, M. et al. Presymptomatic ALS genetic counseling and testing: Experience and 1299 
recommendations. Neurology 86, 2295-302 (2016). 1300 
175. Miller, R.G. et al. Practice parameter update: the care of the patient with amyotrophic lateral 1301 
sclerosis: drug, nutritional, and respiratory therapies (an evidence-based review): report of the 1302 
Quality Standards Subcommittee of the American Academy of Neurology. Neurology 73, 1218-1303 
26 (2009). 1304 
176. Andersen, P.M. et al. EFNS guidelines on the clinical management of amyotrophic lateral 1305 
sclerosis (MALS)--revised report of an EFNS task force. Eur J Neurol 19, 360-75 (2012). 1306 
177. Traynor, B.J., Alexander, M., Corr, B., Frost, E. & Hardiman, O. Effect of a multidisciplinary 1307 
amyotrophic lateral sclerosis (ALS) clinic on ALS survival: a population based study, 1996-2000. J 1308 
Neurol Neurosurg Psychiatry 74, 1258-61 (2003). 1309 
178. Chio, A., Bottacchi, E., Buffa, C., Mutani, R. & Mora, G. Positive effects of tertiary centres for 1310 
amyotrophic lateral sclerosis on outcome and use of hospital facilities. J Neurol Neurosurg 1311 
Psychiatry 77, 948-50 (2006). 1312 
179. Rooney, J. et al. A multidisciplinary clinic approach improves survival in ALS: a comparative study 1313 
of ALS in Ireland and Northern Ireland. J Neurol Neurosurg Psychiatry 86, 496-501 (2015). 1314 
180. Van den Berg, J.P. et al. Multidisciplinary ALS care improves quality of life in patients with ALS. 1315 
Neurology 65, 1264-7 (2005). 1316 
181. Beghi, E. et al. The epidemiology and treatment of ALS: focus on the heterogeneity of the 1317 
disease and critical appraisal of therapeutic trials. Amyotroph Lateral Scler 12, 1-10 (2011). 1318 
182. Lacomblez, L., Bensimon, G., Leigh, P.N., Guillet, P. & Meininger, V. Dose-ranging study of 1319 
riluzole in amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis/Riluzole Study Group II. 1320 
Lancet 347, 1425-31 (1996). 1321 
183. Dyer, A.M. & Smith, A. Riluzole 5 mg/mL oral suspension: for optimized drug delivery in 1322 
amyotrophic lateral sclerosis. Drug Des Devel Ther 11, 59-64 (2017). 1323 
184. Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: a 1324 
randomised, double-blind, placebo-controlled trial. Lancet Neurol 16, 505-512 (2017). 1325 
185. Hardiman, O. & van den Berg, L.H. Edaravone: a new treatment for ALS on the horizon? Lancet 1326 
Neurol 16, 490-491 (2017). 1327 
186. Smith, R. et al. Enhanced Bulbar Function in Amyotrophic Lateral Sclerosis: The Nuedexta 1328 
Treatment Trial. Neurotherapeutics 14, 762-772 (2017). 1329 
187. Amtmann, D., Weydt, P., Johnson, K.L., Jensen, M.P. & Carter, G.T. Survey of cannabis use in 1330 
patients with amyotrophic lateral sclerosis. Am J Hosp Palliat Care 21, 95-104 (2004). 1331 
188. Jackson, C.E. et al. Randomized double-blind study of botulinum toxin type B for sialorrhea in 1332 
ALS patients. Muscle Nerve 39, 137-43 (2009). 1333 
189. Guidubaldi, A. et al. Botulinum toxin A versus B in sialorrhea: a prospective, randomized, 1334 
double-blind, crossover pilot study in patients with amyotrophic lateral sclerosis or Parkinson's 1335 
disease. Mov Disord 26, 313-9 (2011). 1336 
190. Weikamp, J.G. et al. Botulinum toxin-A injections vs radiotherapy for drooling in ALS. Acta 1337 
Neurol Scand 134, 224-31 (2016). 1338 
  42 
191. Chio, A., Mora, G. & Lauria, G. Pain in amyotrophic lateral sclerosis. Lancet Neurol 16, 144-157 1339 
(2017). 1340 
192. Stephens, H.E., Joyce, N.C. & Oskarsson, B. National Study of Muscle Cramps in ALS in the USA. 1341 
Amyotroph Lateral Scler Frontotemporal Degener 18, 32-36 (2017). 1342 
193. Weiss, M.D. et al. A randomized trial of mexiletine in ALS: Safety and effects on muscle cramps 1343 
and progression. Neurology 86, 1474-81 (2016). 1344 
194. Fujimura-Kiyono, C. et al. Onset and spreading patterns of lower motor neuron involvements 1345 
predict survival in sporadic amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry 82, 1346 
1244-9 (2011). 1347 
195. Group, P.S. Gastrostomy in patients with amyotrophic lateral sclerosis (ProGas): a prospective 1348 
cohort study. Lancet Neurol 14, 702-9 (2015). 1349 
196. Dorst, J. et al. Percutaneous endoscopic gastrostomy in amyotrophic lateral sclerosis: a 1350 
prospective observational study. J Neurol 262, 849-58 (2015). 1351 
197. Abdelnour-Mallet, M. et al. Safety of home parenteral nutrition in patients with amyotrophic 1352 
lateral sclerosis: a French national survey. Amyotroph Lateral Scler 12, 178-84 (2011). 1353 
198. Juntas-Morales, R., Pageot, N., Alphandery, S. & Camu, W. The Use of Peripherally Inserted 1354 
Central Catheter in Amyotrophic Lateral Sclerosis Patients at a Later Stage. Eur Neurol 77, 87-90 1355 
(2017). 1356 
199. Londral, A., Pinto, A., Pinto, S., Azevedo, L. & De Carvalho, M. Quality of life in amyotrophic 1357 
lateral sclerosis patients and caregivers: Impact of assistive communication from early stages. 1358 
Muscle Nerve 52, 933-41 (2015). 1359 
200. Marchetti, M. & Priftis, K. Brain-computer interfaces in amyotrophic lateral sclerosis: A 1360 
metanalysis. Clin Neurophysiol 126, 1255-63 (2015). 1361 
201. Geronimo, A., Simmons, Z. & Schiff, S.J. Performance predictors of brain-computer interfaces in 1362 
patients with amyotrophic lateral sclerosis. J Neural Eng 13, 026002 (2016). 1363 
202. Qureshi, M.M., Cudkowicz, M.E., Zhang, H. & Raynor, E. Increased incidence of deep venous 1364 
thrombosis in ALS. Neurology 68, 76-7 (2007). 1365 
203. Gladman, M., Dehaan, M., Pinto, H., Geerts, W. & Zinman, L. Venous thromboembolism in 1366 
amyotrophic lateral sclerosis: a prospective study. Neurology 82, 1674-7 (2014). 1367 
204. Gallagher, J.P. Pathologic laughter and crying in ALS: a search for their origin. Acta Neurol Scand 1368 
80, 114-7 (1989). 1369 
205. Pioro, E.P. et al. Dextromethorphan plus ultra low-dose quinidine reduces pseudobulbar affect. 1370 
Ann Neurol 68, 693-702 (2010). 1371 
206. Merrilees, J., Klapper, J., Murphy, J., Lomen-Hoerth, C. & Miller, B.L. Cognitive and behavioral 1372 
challenges in caring for patients with frontotemporal dementia and amyotrophic lateral 1373 
sclerosis. Amyotroph Lateral Scler 11, 298-302 (2010). 1374 
207. Bourke, S.C. et al. Effects of non-invasive ventilation on survival and quality of life in patients 1375 
with amyotrophic lateral sclerosis: a randomised controlled trial. Lancet Neurol 5, 140-7 (2006). 1376 
208. Chio, A. et al. Non-invasive ventilation in amyotrophic lateral sclerosis: a 10 year population 1377 
based study. J Neurol Neurosurg Psychiatry 83, 377-81 (2012). 1378 
209. Rafiq, M.K. et al. A preliminary randomized trial of the mechanical insufflator-exsufflator versus 1379 
breath-stacking technique in patients with amyotrophic lateral sclerosis. Amyotroph Lateral 1380 
Scler Frontotemporal Degener 16, 448-55 (2015). 1381 
210. Simmons, Z. Patient-Perceived Outcomes and Quality of Life in ALS. Neurotherapeutics 12, 394-1382 
402 (2015). 1383 
211. Baile, W.F. et al. SPIKES-A six-step protocol for delivering bad news: application to the patient 1384 
with cancer. Oncologist 5, 302-11 (2000). 1385 
  43 
212. McCluskey, L., Casarett, D. & Siderowf, A. Breaking the news: a survey of ALS patients and their 1386 
caregivers. Amyotroph Lateral Scler Other Motor Neuron Disord 5, 131-5 (2004). 1387 
213. Aoun, S.M. et al. Receiving the news of a diagnosis of motor neuron disease: What does it take 1388 
to make it better? Amyotroph Lateral Scler Frontotemporal Degener 17, 168-78 (2016). 1389 
214. Green, C. et al. Patients' health-related quality-of-life and health state values for motor neurone 1390 
disease/amyotrophic lateral sclerosis. Qual Life Res 12, 565-74 (2003). 1391 
215. Maessen, M. et al. Trends and determinants of end-of-life practices in ALS in the Netherlands. 1392 
Neurology 73, 954-61 (2009). 1393 
216. Wang, L.H. et al. Death with dignity in Washington patients with amyotrophic lateral sclerosis. 1394 
Neurology 87, 2117-2122 (2016). 1395 
217. Neudert, C., Oliver, D., Wasner, M. & Borasio, G.D. The course of the terminal phase in patients 1396 
with amyotrophic lateral sclerosis. J Neurol 248, 612-6 (2001). 1397 
218. Arthur, K.C. et al. Projected increase in amyotrophic lateral sclerosis from 2015 to 2040. Nat 1398 
Commun 7, 12408 (2016). 1399 
219. Schwartz, C.E. & Sprangers, M.A. Methodological approaches for assessing response shift in 1400 
longitudinal health-related quality-of-life research. Soc Sci Med 48, 1531-48 (1999). 1401 
220. Carr, A.J., Gibson, B. & Robinson, P.G. Measuring quality of life: Is quality of life determined by 1402 
expectations or experience? Bmj 322, 1240-3 (2001). 1403 
221. Barclay, R. & Tate, R.B. Response shift recalibration and reprioritization in health-related quality 1404 
of life was identified prospectively in older men with and without stroke. J Clin Epidemiol 67, 1405 
500-7 (2014). 1406 
222. Simmons, Z., Bremer, B.A., Robbins, R.A., Walsh, S.M. & Fischer, S. Quality of life in ALS depends 1407 
on factors other than strength and physical function. Neurology 55, 388-92 (2000). 1408 
223. Korner, S. et al. Speech therapy and communication device: impact on quality of life and mood 1409 
in patients with amyotrophic lateral sclerosis. Amyotroph Lateral Scler Frontotemporal Degener 1410 
14, 20-5 (2013). 1411 
224. Korner, S. et al. Weight loss, dysphagia and supplement intake in patients with amyotrophic 1412 
lateral sclerosis (ALS): impact on quality of life and therapeutic options. BMC Neurol 13, 84 1413 
(2013). 1414 
225. Lyall, R.A. et al. A prospective study of quality of life in ALS patients treated with noninvasive 1415 
ventilation. Neurology 57, 153-6 (2001). 1416 
226. Bourke, S.C., Bullock, R.E., Williams, T.L., Shaw, P.J. & Gibson, G.J. Noninvasive ventilation in ALS: 1417 
indications and effect on quality of life. Neurology 61, 171-7 (2003). 1418 
227. Walsh, S.M., Bremer, B.A., Felgoise, S.H. & Simmons, Z. Religiousness is related to quality of life 1419 
in patients with ALS. Neurology 60, 1527-9 (2003). 1420 
228. Montel, S., Albertini, L. & Spitz, E. Coping strategies in relation to quality of life in amyotrophic 1421 
lateral sclerosis. Muscle Nerve 45, 131-4 (2012). 1422 
229. Felgoise, S.H. et al. Psychological morbidity in ALS: the importance of psychological assessment 1423 
beyond depression alone. Amyotroph Lateral Scler 11, 351-8 (2010). 1424 
230. Pagnini, F., Simmons, Z., Corbo, M. & Molinari, E. Amyotrophic lateral sclerosis: time for 1425 
research on psychological intervention? Amyotroph Lateral Scler 13, 416-7 (2012). 1426 
231. Mandler, R.N. et al. The ALS Patient Care Database: insights into end-of-life care in ALS. 1427 
Amyotroph Lateral Scler Other Motor Neuron Disord 2, 203-8 (2001). 1428 
232. Ferraiuolo, L., Kirby, J., Grierson, A.J., Sendtner, M. & Shaw, P.J. Molecular pathways of motor 1429 
neuron injury in amyotrophic lateral sclerosis. Nat Rev Neurol 7, 616-30 (2011). 1430 
233. Tsang, C.K., Liu, Y., Thomas, J., Zhang, Y. & Zheng, X.F. Superoxide dismutase 1 acts as a nuclear 1431 
transcription factor to regulate oxidative stress resistance. Nat Commun 5, 3446 (2014). 1432 
  44 
234. Lee, S. & Kim, H.J. Prion-like Mechanism in Amyotrophic Lateral Sclerosis: are Protein Aggregates 1433 
the Key? Exp Neurobiol 24, 1-7 (2015). 1434 
235. Rosen, D.R. Mutations in Cu/Zn superoxide dismutase gene are associated with familial 1435 
amyotrophic lateral sclerosis. Nature 364, 362 (1993). 1436 
236. Siddique, T. et al. Linkage of a gene causing familial amyotrophic lateral sclerosis to 1437 
chromosome 21 and evidence of genetic-locus heterogeneity. N Engl J Med 324, 1381-4 (1991). 1438 
237. Hadano, S. et al. A gene encoding a putative GTPase regulator is mutated in familial amyotrophic 1439 
lateral sclerosis 2. Nat Genet 29, 166-73 (2001). 1440 
238. Yang, Y. et al. The gene encoding alsin, a protein with three guanine-nucleotide exchange factor 1441 
domains, is mutated in a form of recessive amyotrophic lateral sclerosis. Nat Genet 29, 160-5 1442 
(2001). 1443 
239. Hand, C.K. et al. A novel locus for familial amyotrophic lateral sclerosis, on chromosome 18q. Am 1444 
J Hum Genet 70, 251-6 (2002). 1445 
240. Chen, Y.Z. et al. DNA/RNA helicase gene mutations in a form of juvenile amyotrophic lateral 1446 
sclerosis (ALS4). Am J Hum Genet 74, 1128-35 (2004). 1447 
241. Hentati, A. et al. Linkage of recessive familial amyotrophic lateral sclerosis to chromosome 2q33-1448 
q35. Nat Genet 7, 425-8 (1994). 1449 
242. Kwiatkowski, T.J., Jr. et al. Mutations in the FUS/TLS gene on chromosome 16 cause familial 1450 
amyotrophic lateral sclerosis. Science 323, 1205-8 (2009). 1451 
243. Vance, C. et al. Mutations in FUS, an RNA processing protein, cause familial amyotrophic lateral 1452 
sclerosis type 6. Science 323, 1208-11 (2009). 1453 
244. Sapp, P.C. et al. Identification of two novel loci for dominantly inherited familial amyotrophic 1454 
lateral sclerosis. Am J Hum Genet 73, 397-403 (2003). 1455 
245. Greenway, M.J. et al. ANG mutations segregate with familial and 'sporadic' amyotrophic lateral 1456 
sclerosis. Nat Genet 38, 411-3 (2006). 1457 
246. Sreedharan, J. et al. TDP-43 mutations in familial and sporadic amyotrophic lateral sclerosis. 1458 
Science 319, 1668-72 (2008). 1459 
247. Chow, C.Y. et al. Deleterious variants of FIG4, a phosphoinositide phosphatase, in patients with 1460 
ALS. Am J Hum Genet 84, 85-8 (2009). 1461 
248. Maruyama, H. et al. Mutations of optineurin in amyotrophic lateral sclerosis. Nature 465, 223-6 1462 
(2010). 1463 
249. Elden, A.C. et al. Ataxin-2 intermediate-length polyglutamine expansions are associated with 1464 
increased risk for ALS. Nature 466, 1069-75 (2010). 1465 
250. Luty, A.A. et al. Sigma nonopioid intracellular receptor 1 mutations cause frontotemporal lobar 1466 
degeneration-motor neuron disease. Ann Neurol 68, 639-49 (2010). 1467 
251. Al-Saif, A., Al-Mohanna, F. & Bohlega, S. A mutation in sigma-1 receptor causes juvenile 1468 
amyotrophic lateral sclerosis. Ann Neurol 70, 913-9 (2011). 1469 
252. Parkinson, N. et al. ALS phenotypes with mutations in CHMP2B (charged multivesicular body 1470 
protein 2B). Neurology 67, 1074-7 (2006). 1471 
253. Takahashi, Y. et al. ERBB4 mutations that disrupt the neuregulin-ErbB4 pathway cause 1472 
amyotrophic lateral sclerosis type 19. Am J Hum Genet 93, 900-5 (2013). 1473 
254. Renton, A.E. et al. A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 1474 
9p21-linked ALS-FTD. Neuron 72, 257-68 (2011). 1475 
255. Bannwarth, S. et al. A mitochondrial origin for frontotemporal dementia and amyotrophic lateral 1476 
sclerosis through CHCHD10 involvement. Brain 137, 2329-45 (2014). 1477 
256. Fecto, F. et al. SQSTM1 mutations in familial and sporadic amyotrophic lateral sclerosis. Arch 1478 
Neurol 68, 1440-6 (2011). 1479 
  45 
  1480 
